EP4384160A1 - Composés hétérocycliques et procédés d'utilisation - Google Patents
Composés hétérocycliques et procédés d'utilisationInfo
- Publication number
- EP4384160A1 EP4384160A1 EP22856568.5A EP22856568A EP4384160A1 EP 4384160 A1 EP4384160 A1 EP 4384160A1 EP 22856568 A EP22856568 A EP 22856568A EP 4384160 A1 EP4384160 A1 EP 4384160A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fluoro
- methoxy
- pyrimidin
- pyrido
- pyrrolizin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 96
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 587
- 239000000203 mixture Substances 0.000 claims abstract description 103
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- 201000011510 cancer Diseases 0.000 claims abstract description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 35
- 102200006539 rs121913529 Human genes 0.000 claims abstract description 19
- -1 -N(Rz)2 Chemical group 0.000 claims description 993
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 79
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 42
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 239000011737 fluorine Chemical group 0.000 claims description 26
- 229910052731 fluorine Inorganic materials 0.000 claims description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000004043 oxo group Chemical group O=* 0.000 claims description 22
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 19
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 18
- WPQZECZBRLTWLB-UEUFWECKSA-N 3-(difluoromethyl)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)CC3(C(F)F)O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F WPQZECZBRLTWLB-UEUFWECKSA-N 0.000 claims description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 17
- 125000002947 alkylene group Chemical group 0.000 claims description 17
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 14
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 14
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 14
- 201000002528 pancreatic cancer Diseases 0.000 claims description 14
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 14
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 12
- FQCBKNNQESATFV-JWHYFAEWSA-N C[C@@](CCC1)(CN1C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C(C1=C3F)=CC(O)=CC1=CC=C3F)=C2F)O Chemical compound C[C@@](CCC1)(CN1C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C(C1=C3F)=CC(O)=CC1=CC=C3F)=C2F)O FQCBKNNQESATFV-JWHYFAEWSA-N 0.000 claims description 11
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 10
- GVWZOCVRICLHPR-SSTSUWDTSA-N 1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-5,5-difluoropiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CC(C3)O)CC3(F)F)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F GVWZOCVRICLHPR-SSTSUWDTSA-N 0.000 claims description 10
- 206010014733 Endometrial cancer Diseases 0.000 claims description 9
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 9
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 9
- 102000008300 Mutant Proteins Human genes 0.000 claims description 9
- 108010021466 Mutant Proteins Proteins 0.000 claims description 9
- 208000021780 appendiceal neoplasm Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 201000002313 intestinal cancer Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 8
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- IZXWMVPZODQBRB-UHFFFAOYSA-N piperidine-3,4-diol Chemical compound OC1CCNCC1O IZXWMVPZODQBRB-UHFFFAOYSA-N 0.000 claims description 8
- LQNXWMPOTKRVOW-JXNPFXPLSA-N 4-[4-(azocan-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethyl-6-fluoronaphthalen-2-ol Chemical compound CCC1=C2C(C(N=CC(C(N3CCCCCCC3)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F LQNXWMPOTKRVOW-JXNPFXPLSA-N 0.000 claims description 7
- 239000005977 Ethylene Substances 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- 239000000460 chlorine Chemical group 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- KOEDAUSLINGWBJ-WLDISPQGSA-N (3R)-1-[7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound C[C@@](CCC1)(CN1C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C(C1=C3C#C)=CC=CC1=CC=C3F)=C2F)O KOEDAUSLINGWBJ-WLDISPQGSA-N 0.000 claims description 6
- UQAXJMLMNBQVGM-JPRSJLJBSA-N (3R,6R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-6-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(C3)[C@H](C)CC[C@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F UQAXJMLMNBQVGM-JPRSJLJBSA-N 0.000 claims description 6
- UQAXJMLMNBQVGM-WTIUKSEPSA-N (3R,6S)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-6-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(C3)[C@@H](C)CC[C@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F UQAXJMLMNBQVGM-WTIUKSEPSA-N 0.000 claims description 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 6
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 6
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 6
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 201000003115 germ cell cancer Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- CCSBGJSFNYQQFU-WJOKGBTCSA-N (3R)-1-[2-[[1-[(dimethylamino)methyl]cyclopropyl]methoxy]-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OCC3(CN(C)C)CC3)=C4F)=CC(O)=CC2=CC=C1F CCSBGJSFNYQQFU-WJOKGBTCSA-N 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- PVWFUKXETRSKBM-ZDKWMYCKSA-N 1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]azepan-4-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)CCC3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F PVWFUKXETRSKBM-ZDKWMYCKSA-N 0.000 claims description 5
- OVKXDANNQWXYKF-UHFFFAOYSA-N 2-methyloctanamide Chemical compound CCCCCCC(C)C(N)=O OVKXDANNQWXYKF-UHFFFAOYSA-N 0.000 claims description 5
- DALZRLVOYLOQPS-ONTKHRELSA-N CCC1=C2C(C(N=CC(C(N(CCC3)C[C@@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F DALZRLVOYLOQPS-ONTKHRELSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- SXNMNJGBKPGDPH-UHFFFAOYSA-N 1,2,3a,4,5,6,7,7a-octahydropyrrolo[3,4-c]pyridin-3-one Chemical compound C1CNCC2C(=O)NCC21 SXNMNJGBKPGDPH-UHFFFAOYSA-N 0.000 claims description 4
- XSDYEQRSHRREDD-FKNOXORPSA-N 4-[4-(3-azabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethyl-6-fluoronaphthalen-2-ol Chemical compound CCC1=C2C(C(N=CC(C(N3CC(CC4)CC4C3)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F XSDYEQRSHRREDD-FKNOXORPSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 208000011825 carcinoma of the ampulla of vater Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 5
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 159
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 98
- 238000006243 chemical reaction Methods 0.000 description 80
- 235000019439 ethyl acetate Nutrition 0.000 description 76
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 70
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 64
- 239000003112 inhibitor Substances 0.000 description 64
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 55
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 54
- 239000007787 solid Substances 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 48
- 239000000741 silica gel Substances 0.000 description 46
- 229910002027 silica gel Inorganic materials 0.000 description 46
- 239000000543 intermediate Substances 0.000 description 45
- 238000004440 column chromatography Methods 0.000 description 40
- 230000002829 reductive effect Effects 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 239000000047 product Substances 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 25
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 239000013058 crude material Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 102000001301 EGF receptor Human genes 0.000 description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- 229910052938 sodium sulfate Inorganic materials 0.000 description 21
- 108060006698 EGF receptor Proteins 0.000 description 20
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 19
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- 239000007832 Na2SO4 Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 238000004007 reversed phase HPLC Methods 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 16
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 15
- 239000003039 volatile agent Substances 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 150000002081 enamines Chemical class 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 102000009076 src-Family Kinases Human genes 0.000 description 12
- 108010087686 src-Family Kinases Proteins 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 229940043355 kinase inhibitor Drugs 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 125000001153 fluoro group Chemical group F* 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 9
- 102200006538 rs121913530 Human genes 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 8
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 229940123690 Raf kinase inhibitor Drugs 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 description 7
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 description 7
- 102200006531 rs121913529 Human genes 0.000 description 7
- 102200006537 rs121913529 Human genes 0.000 description 7
- 102200006541 rs121913530 Human genes 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- ILTXDPMYCUSDQV-UHFFFAOYSA-N 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine Chemical compound C1(=C(C2=C(C=N1)C(Cl)=NC(=N2)Cl)F)Cl ILTXDPMYCUSDQV-UHFFFAOYSA-N 0.000 description 6
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 6
- GGFLAUXTEQHVKF-UHFFFAOYSA-N 2-[8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C(C)C=1C(=CC=C2C=C(C=C(C=12)B1OC(C(O1)(C)C)(C)C)OCOC)F GGFLAUXTEQHVKF-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 239000012270 PD-1 inhibitor Substances 0.000 description 6
- 239000012668 PD-1-inhibitor Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 6
- 229940121655 pd-1 inhibitor Drugs 0.000 description 6
- 229910000160 potassium phosphate Inorganic materials 0.000 description 6
- 235000011009 potassium phosphates Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010626 work up procedure Methods 0.000 description 6
- NSCBVPULCFBFGX-FYZOBXCZSA-N Cl.C[C@@]1(O)CCCNC1 Chemical compound Cl.C[C@@]1(O)CCCNC1 NSCBVPULCFBFGX-FYZOBXCZSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 5
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 5
- 239000012271 PD-L1 inhibitor Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940124302 mTOR inhibitor Drugs 0.000 description 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 5
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- HUNGUWOZPQBXGX-UHFFFAOYSA-N tirbanibulin Chemical compound C=1C=CC=CC=1CNC(=O)CC(N=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCOCC1 HUNGUWOZPQBXGX-UHFFFAOYSA-N 0.000 description 5
- KQCKHQZWOXVVTG-QNRUXRNSSA-N 1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]azepane-4-carbonitrile Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)CCC3C#N)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F KQCKHQZWOXVVTG-QNRUXRNSSA-N 0.000 description 4
- OLWOCKPSXABRQJ-UHFFFAOYSA-N 1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]azepan-4-ol Chemical compound OC(CCC1)CCN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F OLWOCKPSXABRQJ-UHFFFAOYSA-N 0.000 description 4
- CTZPMSFNSOYSRF-PJLBITLMSA-N 3-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-azabicyclo[3.2.1]octan-6-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CC(C3)C4)CC3C4O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F CTZPMSFNSOYSRF-PJLBITLMSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 102000004000 Aurora Kinase A Human genes 0.000 description 4
- 108090000461 Aurora Kinase A Proteins 0.000 description 4
- 239000012824 ERK inhibitor Substances 0.000 description 4
- 229940124783 FAK inhibitor Drugs 0.000 description 4
- 101001091231 Homo sapiens Kinesin-like protein KIF18A Proteins 0.000 description 4
- 229940126262 KIF18A Drugs 0.000 description 4
- 102100034895 Kinesin-like protein KIF18A Human genes 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 239000012828 PI3K inhibitor Substances 0.000 description 4
- QAJRFPVPHUYVFE-SFYZADRCSA-N [(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methanol Chemical compound F[C@@H]1C[C@@]2(CCCN2C1)CO QAJRFPVPHUYVFE-SFYZADRCSA-N 0.000 description 4
- HISJAYUQVHMWTA-BLLLJJGKSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol Chemical compound NC1=NC=CC(=C1Cl)SC1=C(N=C(C(=N1)CO)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- VRURZGYOOPPNNT-UHFFFAOYSA-N benzyl 3-hydroxy-3-methylazepane-1-carboxylate Chemical compound CC1(O)CCCCN(C1)C(=O)OCC1=CC=CC=C1 VRURZGYOOPPNNT-UHFFFAOYSA-N 0.000 description 4
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- SELYJABLPLKXOY-UHFFFAOYSA-N methyl n,n-dimethylcarbamate Chemical compound COC(=O)N(C)C SELYJABLPLKXOY-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000003197 protein kinase B inhibitor Substances 0.000 description 4
- PLZDHJUUEGCXJH-UHFFFAOYSA-N pyrido[4,3-d]pyrimidine Chemical compound C1=NC=C2C=NC=CC2=N1 PLZDHJUUEGCXJH-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- KDHQVJZDQNGTHF-CYBMUJFWSA-N (3R)-1-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol Chemical compound C[C@@](CCC1)(CN1C1=NC(Cl)=NC2=C1C=NC(Cl)=C2F)O KDHQVJZDQNGTHF-CYBMUJFWSA-N 0.000 description 3
- PAJYQJABIFAGCO-LTDULLJHSA-N (3R,5R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]piperidine-3,5-diol Chemical compound CCC1=C2C(C(N=CC(C(N(C[C@@H](C3)O)C[C@@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F PAJYQJABIFAGCO-LTDULLJHSA-N 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- DOHYFSCMTDZXIL-UHFFFAOYSA-N 7-fluoro-8-[2-tri(propan-2-yl)silylethynyl]naphthalen-1-ol Chemical compound FC1=CC=C2C=CC=C(C2=C1C#C[Si](C(C)C)(C(C)C)C(C)C)O DOHYFSCMTDZXIL-UHFFFAOYSA-N 0.000 description 3
- DIYWCGZFCFYCIE-UHFFFAOYSA-N 8-bromo-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=CC=C2Br DIYWCGZFCFYCIE-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YWMZWUBUTHFVHH-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=1C2=C(N=C(N=1)Cl)C(=C(N=C2)Cl)F Chemical compound C(C1=CC=CC=C1)OC=1C2=C(N=C(N=1)Cl)C(=C(N=C2)Cl)F YWMZWUBUTHFVHH-UHFFFAOYSA-N 0.000 description 3
- DCLRDPOCXQPYAB-UHFFFAOYSA-N CC(C)[Si](C(C)C)(C(C)C)C#CC1=C2C(OC(C(C)(C)C)=O)=CC=CC2=CC=C1F Chemical compound CC(C)[Si](C(C)C)(C(C)C)C#CC1=C2C(OC(C(C)(C)C)=O)=CC=CC2=CC=C1F DCLRDPOCXQPYAB-UHFFFAOYSA-N 0.000 description 3
- BMFRNUZUTBDWFN-UHFFFAOYSA-N CC(C)[Si](C(C)C)(C(C)C)OC(C=C(C1=C2F)O)=CC1=CC=C2F Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC(C=C(C1=C2F)O)=CC1=CC=C2F BMFRNUZUTBDWFN-UHFFFAOYSA-N 0.000 description 3
- KEEDNFKUZKXARW-UHFFFAOYSA-N CC(C)[Si](C(C)C)(C(C)C)OC(C=C(C1=C2F)OS(C(F)(F)F)(=O)=O)=CC1=CC=C2F Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC(C=C(C1=C2F)OS(C(F)(F)F)(=O)=O)=CC1=CC=C2F KEEDNFKUZKXARW-UHFFFAOYSA-N 0.000 description 3
- YCJYXRRWMYMDEQ-UHFFFAOYSA-N CC(C1=C(CC(OC)=O)C=CC(F)=C1F)=O Chemical compound CC(C1=C(CC(OC)=O)C=CC(F)=C1F)=O YCJYXRRWMYMDEQ-UHFFFAOYSA-N 0.000 description 3
- RAHKEEYHEGAETG-UHFFFAOYSA-N CCC1=C(C(B2OC(C)(C)C(C)(C)O2)=CC=C2)C2=CC=C1F Chemical compound CCC1=C(C(B2OC(C)(C)C(C)(C)O2)=CC=C2)C2=CC=C1F RAHKEEYHEGAETG-UHFFFAOYSA-N 0.000 description 3
- CKZLBQXJHIINPY-UHFFFAOYSA-N CCC1=C2C(O)=CC=CC2=CC=C1F Chemical compound CCC1=C2C(O)=CC=CC2=CC=C1F CKZLBQXJHIINPY-UHFFFAOYSA-N 0.000 description 3
- WIQOELDPGGWZCH-UHFFFAOYSA-N CCC1=C2C(OS(C(F)(F)F)(=O)=O)=CC=CC2=CC=C1F Chemical compound CCC1=C2C(OS(C(F)(F)F)(=O)=O)=CC=CC2=CC=C1F WIQOELDPGGWZCH-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 229940124647 MEK inhibitor Drugs 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 3
- NHSNMMLPCUOVFK-UHFFFAOYSA-N OC(C=C1C=C2)=CC(Br)=C1C(Cl)=C2F Chemical compound OC(C=C1C=C2)=CC(Br)=C1C(Cl)=C2F NHSNMMLPCUOVFK-UHFFFAOYSA-N 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- RNCWUCLVGQXQOP-UHFFFAOYSA-N methyl 2-(2-bromo-3,4-difluorophenyl)acetate Chemical compound COC(=O)CC1=CC=C(F)C(F)=C1Br RNCWUCLVGQXQOP-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- ASVDQAKFEZAPKZ-ZRSZIQLQSA-N (2R,3R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-2-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)[C@H](C)[C@@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F ASVDQAKFEZAPKZ-ZRSZIQLQSA-N 0.000 description 2
- VSWLAEZTFHETFD-KTBRYMIGSA-N (2R,8S)-8-[[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-piperidin-1-ylpyrido[4,3-d]pyrimidin-2-yl]oxymethyl]-1,2,3,5,6,7-hexahydropyrrolizin-2-ol Chemical compound CCC1=C2C(C(N=CC(C(N3CCCCC3)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5O)=C4F)=CC(O)=CC2=CC=C1F VSWLAEZTFHETFD-KTBRYMIGSA-N 0.000 description 2
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 2
- RUSZJPMZSJNPFZ-GUGRHCGGSA-N (3R)-1-[7-(1H-benzo[f]indazol-4-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound C[C@@](CCC1)(CN1C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C1=C(C=NN3)C3=CC3=C1C=CC=C3)=C2F)O RUSZJPMZSJNPFZ-GUGRHCGGSA-N 0.000 description 2
- RZYWNBKMTZABBP-PAXFXPPDSA-N (3R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F RZYWNBKMTZABBP-PAXFXPPDSA-N 0.000 description 2
- LKEFGLZZUXSDPT-QPHCHLROSA-N (3R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OC[C@H]3N(C)CCC3)=C4F)=CC(O)=CC2=CC=C1F LKEFGLZZUXSDPT-QPHCHLROSA-N 0.000 description 2
- RFXDUBOVRRMGGS-WLDISPQGSA-N (3R)-1-[7-(8-ethyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC=CC2=CC=C1F RFXDUBOVRRMGGS-WLDISPQGSA-N 0.000 description 2
- RBBGILDTJIYRIY-JGCGQSQUSA-N (3R)-1-[7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound C[C@@](CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C(C1=C3C#C)=CC=CC1=CC=C3F)=C2F)O RBBGILDTJIYRIY-JGCGQSQUSA-N 0.000 description 2
- MMEMQBKTAIAORE-NUBCRITNSA-N (3R)-piperidine-3-sulfonamide hydrochloride Chemical compound Cl.NS(=O)(=O)[C@@H]1CCCNC1 MMEMQBKTAIAORE-NUBCRITNSA-N 0.000 description 2
- VKEBTLJBGAWKOF-OJQXBTCOSA-N (3R,5R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-5-fluoropiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(C[C@@H](C3)O)C[C@@H]3F)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F VKEBTLJBGAWKOF-OJQXBTCOSA-N 0.000 description 2
- NRUNSXVWGQYJSP-PZJWPPBQSA-N (3R,5S)-1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-5-methylpiperidin-3-ol Chemical compound C[C@@H](C[C@H](C1)O)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F NRUNSXVWGQYJSP-PZJWPPBQSA-N 0.000 description 2
- OHSMPALYRUEVLJ-BGYRXZFFSA-N (3R,5S)-1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidine-3,5-diol Chemical compound O[C@H](C[C@@H](C1)O)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F OHSMPALYRUEVLJ-BGYRXZFFSA-N 0.000 description 2
- NTSVQFMGOWLTJC-AZUAARDMSA-N (3R,5S)-5-[[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-piperidin-1-ylpyrido[4,3-d]pyrimidin-2-yl]oxymethyl]-1-methylpyrrolidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N3CCCCC3)=N3)=C4N=C3OC[C@H](C3)N(C)C[C@@H]3O)=C4F)=CC(O)=CC2=CC=C1F NTSVQFMGOWLTJC-AZUAARDMSA-N 0.000 description 2
- RZYWNBKMTZABBP-TVNPGVRDSA-N (3S)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@@]3(C)O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F RZYWNBKMTZABBP-TVNPGVRDSA-N 0.000 description 2
- QJDACQFXSBFQJB-TVNPGVRDSA-N (3S)-1-[7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound C[C@](CCC1)(CN1C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C(C1=C3C#C)=CC(O)=CC1=CC=C3F)=C2F)O QJDACQFXSBFQJB-TVNPGVRDSA-N 0.000 description 2
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 description 2
- AMKQJMLIEOFOHW-GOSISDBHSA-N (4R)-8-[5-(2,3-dichlorophenyl)-6-methylimidazo[1,5-a]pyrazin-8-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound CC1=C(N2C=NC=C2C(=N1)N1CCC2(CCC[C@H]2N)CC1)C1=C(Cl)C(Cl)=CC=C1 AMKQJMLIEOFOHW-GOSISDBHSA-N 0.000 description 2
- QDITZBLZQQZVEE-YBEGLDIGSA-N (5z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=C2C=3C=CN=CC=3)C2=C1 QDITZBLZQQZVEE-YBEGLDIGSA-N 0.000 description 2
- 125000006712 (C1-C4) deuteroalkyl group Chemical group 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- NERXPXBELDBEPZ-RMKNXTFCSA-N (e)-n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 NERXPXBELDBEPZ-RMKNXTFCSA-N 0.000 description 2
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 2
- AHPVHEAQLFAZOC-UHFFFAOYSA-N 1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethanol Chemical compound C1CCN2CCCC21CO AHPVHEAQLFAZOC-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical group C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical group C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- FAYAUAZLLLJJGH-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[5-[2-(4-thieno[3,2-d]pyrimidinylamino)ethyl]-2-thiazolyl]urea Chemical compound ClC1=CC=CC(NC(=O)NC=2SC(CCNC=3C=4SC=CC=4N=CN=3)=CN=2)=C1 FAYAUAZLLLJJGH-UHFFFAOYSA-N 0.000 description 2
- KYYKGSDLXXKQCR-UHFFFAOYSA-N 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea Chemical compound N1=C(C(C)(C)C)C=C(NC(=O)NC=2C(=CC(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)F)N1C1=CC=CC=C1 KYYKGSDLXXKQCR-UHFFFAOYSA-N 0.000 description 2
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 description 2
- UURQBDPOVSSXEC-UHFFFAOYSA-N 1-[7-(2-amino-1,3-benzothiazol-4-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=C1N=C(N)S3)=C2F)O UURQBDPOVSSXEC-UHFFFAOYSA-N 0.000 description 2
- MBUUZUSHBBXIRD-UHFFFAOYSA-N 1-[7-(2-amino-5,6-dimethyl-1,3-benzothiazol-4-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=C(C)C(C)=CC3=C1N=C(N)S3)=C2F)O MBUUZUSHBBXIRD-UHFFFAOYSA-N 0.000 description 2
- VKGZVCKDYIMNTI-NIEDPTGLSA-N 1-[7-(2-amino-5,6-dimethyl-1,3-benzothiazol-4-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C1=C(C)C(C)=CC3=C1N=C(N)S3)=C2F)O VKGZVCKDYIMNTI-NIEDPTGLSA-N 0.000 description 2
- LLWLMWQPVGIDQO-UHFFFAOYSA-N 1-[7-(3-chloro-2-cyclopropyl-5-hydroxyphenyl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=C(C3CC3)C(Cl)=CC(O)=C1)=C2F)O LLWLMWQPVGIDQO-UHFFFAOYSA-N 0.000 description 2
- KGINNKWJCHJISS-UHFFFAOYSA-N 1-[7-(8-chloronaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(Cl)=C13)=C2F)O KGINNKWJCHJISS-UHFFFAOYSA-N 0.000 description 2
- IWKIETGMCFZFHX-UHFFFAOYSA-N 1-[7-(8-ethylnaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)CC3(C)O)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 IWKIETGMCFZFHX-UHFFFAOYSA-N 0.000 description 2
- QMGCMRIWEBRFLP-UHFFFAOYSA-N 1-[7-(8-ethynylnaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(C#C)=C13)=C2F)O QMGCMRIWEBRFLP-UHFFFAOYSA-N 0.000 description 2
- LDDNVFVLUSDXOE-FANSYELNSA-N 1-[7-[3-chloro-5-hydroxy-2-[(1S,2R)-2-methylcyclopropyl]phenyl]-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound C[C@H](C1)[C@H]1C(C(Cl)=CC(O)=C1)=C1C(N=CC(C(N(CCC1)CC1(C)O)=N1)=C2N=C1OCC1(CCC3)N3CCC1)=C2F LDDNVFVLUSDXOE-FANSYELNSA-N 0.000 description 2
- VORILUWGOZWWMW-UHFFFAOYSA-N 1-[8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-7-naphthalen-1-ylpyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC=C13)=C2F)O VORILUWGOZWWMW-UHFFFAOYSA-N 0.000 description 2
- RTBYFKQOORPMOE-UHFFFAOYSA-N 1-[8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-7-quinolin-8-ylpyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=C3N=CC=CC3=CC=C1)=C2F)O RTBYFKQOORPMOE-UHFFFAOYSA-N 0.000 description 2
- NIIZSNXOUUUALQ-UHFFFAOYSA-N 1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-(hydroxymethyl)piperidin-4-ol Chemical compound OCC(CN(CC1)C2=NC(OCC3(CCC4)N4CCC3)=NC3=C2C=NC(C2=CC=CC4=CC=CC(F)=C24)=C3F)C1O NIIZSNXOUUUALQ-UHFFFAOYSA-N 0.000 description 2
- PKORKBYQHKLMHN-UHFFFAOYSA-N 1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F)O PKORKBYQHKLMHN-UHFFFAOYSA-N 0.000 description 2
- BIGLJMHIFSSAGW-UHFFFAOYSA-N 1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]azepane-4-carbonitrile Chemical compound N#CC(CCC1)CCN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F BIGLJMHIFSSAGW-UHFFFAOYSA-N 0.000 description 2
- YZBZOFNGDHZRHM-UHFFFAOYSA-N 1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-4-ol Chemical compound OC(CC1)CCN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F YZBZOFNGDHZRHM-UHFFFAOYSA-N 0.000 description 2
- RFCMZRXRRNZDHV-UHFFFAOYSA-N 1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidine-3-carboxamide Chemical compound NC(C(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F)=O RFCMZRXRRNZDHV-UHFFFAOYSA-N 0.000 description 2
- RGJOJUGRHPQXGF-INIZCTEOSA-N 1-ethyl-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-7-(oxetan-3-yl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea Chemical compound C1=CC(NC(=O)NCC)=CC=C1C(N=C1N2[C@H](COCC2)C)=NC2=C1CCN(C1COC1)C2 RGJOJUGRHPQXGF-INIZCTEOSA-N 0.000 description 2
- UKANCZCEGQDKGF-UHFFFAOYSA-N 1-methylpiperidin-3-ol Chemical compound CN1CCCC(O)C1 UKANCZCEGQDKGF-UHFFFAOYSA-N 0.000 description 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
- ZVPDNRVYHLRXLX-UHFFFAOYSA-N 1-ter-butyl-3-p-tolyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine Chemical compound C1=CC(C)=CC=C1C1=NN(C(C)(C)C)C2=NC=NC(N)=C12 ZVPDNRVYHLRXLX-UHFFFAOYSA-N 0.000 description 2
- VLULRUCCHYVXOH-UHFFFAOYSA-N 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one Chemical compound CC1=CC=CC=C1CN1C(=O)C(CN(CC=2C=CC=CC=2)CC2)=C2N2CCN=C21 VLULRUCCHYVXOH-UHFFFAOYSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- XKUMDCWNTYSFME-UHFFFAOYSA-N 2,3,6,7-tetrahydro-1h-azepine;hydrochloride Chemical compound Cl.C1CC=CCCN1 XKUMDCWNTYSFME-UHFFFAOYSA-N 0.000 description 2
- GVDDZGLICOJWPJ-UHFFFAOYSA-N 2,4,7-trichloro-8-methylpyrido[4,3-d]pyrimidine Chemical compound ClC=1N=C(C2=C(N=1)C(=C(N=C2)Cl)C)Cl GVDDZGLICOJWPJ-UHFFFAOYSA-N 0.000 description 2
- OLNXMNRGWYWTAF-APPDUMDISA-N 2-(2-amino-3-chloropyridin-4-yl)sulfanyl-5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyridin-3-ol Chemical compound C1C2(CCN(CC2)C2=C(N=C(C(O)=C2)SC2=C(C(=NC=C2)N)Cl)CO)[C@@H]([C@@H](O1)C)N OLNXMNRGWYWTAF-APPDUMDISA-N 0.000 description 2
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 2
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 2
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JBGYKRAZYDNCNV-UHFFFAOYSA-N 2-[4-(1-aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide Chemical compound N12N=C(C(=O)N)C=CC2=NC(C=2C=CC(=CC=2)C2(N)CCC2)=C1C1=CC=CC=C1 JBGYKRAZYDNCNV-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- VDZZYOJYLLNBTD-UHFFFAOYSA-N 2-[4-[[5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidin-2-yl]amino]pyrazol-1-yl]ethanol Chemical compound COC1=CC(OC)=C(F)C(COC=2C=NC(NC3=CN(CCO)N=C3)=NC=2)=C1F VDZZYOJYLLNBTD-UHFFFAOYSA-N 0.000 description 2
- UAXBAGROJKOXRX-UHFFFAOYSA-N 2-[8-chloro-3-(methoxymethoxy)naphthalen-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C1=CC=C2C=C(C=C(B3OC(C(C)(C)O3)(C)C)C2=C1Cl)OCOC UAXBAGROJKOXRX-UHFFFAOYSA-N 0.000 description 2
- FZIKEAIOMDSNBZ-UHFFFAOYSA-N 2-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-1,3-dihydroisoindol-4-ol Chemical compound OC1=CC=CC(C2)=C1CN2C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F FZIKEAIOMDSNBZ-UHFFFAOYSA-N 0.000 description 2
- IGUBBWJDMLCRIK-UHFFFAOYSA-N 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=CC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1C(F)(F)F IGUBBWJDMLCRIK-UHFFFAOYSA-N 0.000 description 2
- BVAHPPKGOOJSPU-UHFFFAOYSA-N 2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1NC1=CC(NC=2N(N=C(C)C=2)C(C)C)=NC=C1Cl BVAHPPKGOOJSPU-UHFFFAOYSA-N 0.000 description 2
- XUMALORDVCFWKV-IBGZPJMESA-N 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 XUMALORDVCFWKV-IBGZPJMESA-N 0.000 description 2
- FIMYFEGKMOCQKT-UHFFFAOYSA-N 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide Chemical compound FC=1C(F)=C(NC=2C(=CC(I)=CC=2)F)C(C(=O)NOCCO)=CC=1CN1OCCCC1=O FIMYFEGKMOCQKT-UHFFFAOYSA-N 0.000 description 2
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 2
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 2
- SWSNEKXJSPHEAP-UHFFFAOYSA-N 3-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-azabicyclo[3.2.1]octan-6-ol Chemical compound OC(CC(C1)C2)C1CN2C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F SWSNEKXJSPHEAP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VPTKEEUVGZDALK-UHFFFAOYSA-N 4-(azocan-1-yl)-8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidine Chemical compound FC1=C2C(C(N=CC(C(N3CCCCCCC3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 VPTKEEUVGZDALK-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 2
- GPSZYOIFQZPWEJ-UHFFFAOYSA-N 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=CC(=CC=3)N3CCOCC3)N=CC=2)=C1C GPSZYOIFQZPWEJ-UHFFFAOYSA-N 0.000 description 2
- RERFGTWQSMXGOK-UHFFFAOYSA-N 5,6-difluoro-4-[8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-4-[3-(5-methyl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]pyrido[4,3-d]pyrimidin-7-yl]naphthalen-2-ol Chemical compound CC1=NNC(C(CCC2)CN2C2=NC(OCC3(CCC4)N4CCC3)=NC3=C2C=NC(C(C2=C4F)=CC(O)=CC2=CC=C4F)=C3F)=N1 RERFGTWQSMXGOK-UHFFFAOYSA-N 0.000 description 2
- WKDACQVEJIVHMZ-UHFFFAOYSA-N 5-(3-ethylsulfonylphenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide Chemical compound CCS(=O)(=O)C1=CC=CC(C=2C=3C4=CC(C)=CN=C4NC=3C(C)=C(C(=O)NC3CCN(C)CC3)C=2)=C1 WKDACQVEJIVHMZ-UHFFFAOYSA-N 0.000 description 2
- RZOJWRSBEIBPBF-GOSISDBHSA-N 5-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-2-(2,3-dichlorophenyl)sulfanyl-6-(hydroxymethyl)pyridin-3-ol Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1C=C(C(=NC=1CO)SC1=C(C(=CC=C1)Cl)Cl)O RZOJWRSBEIBPBF-GOSISDBHSA-N 0.000 description 2
- NGFFVZQXSRKHBM-FKBYEOEOSA-N 5-[[(1r,1as,6br)-1-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)CCC2=C1N=CC=C2OC(C=C1[C@@H]23)=CC=C1O[C@@H]3[C@H]2C1=NC2=CC=C(C(F)(F)F)C=C2N1 NGFFVZQXSRKHBM-FKBYEOEOSA-N 0.000 description 2
- XXSSGBYXSKOLAM-UHFFFAOYSA-N 5-bromo-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide Chemical compound OCC(O)CONC(=O)C1=CC(Br)=C(F)C(F)=C1NC1=CC=C(I)C=C1F XXSSGBYXSKOLAM-UHFFFAOYSA-N 0.000 description 2
- DUSLASQYEJVOLP-UHFFFAOYSA-N 5-methylpiperidine-3-carboxamide hydrochloride Chemical compound Cl.CC1CNCC(C1)C(N)=O DUSLASQYEJVOLP-UHFFFAOYSA-N 0.000 description 2
- JNPRPMBJODOFEC-UHFFFAOYSA-N 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one Chemical compound CC1(N(C(C2=C1SC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)=O)CCN1CCOCC1)C JNPRPMBJODOFEC-UHFFFAOYSA-N 0.000 description 2
- XFBCGMOPRHAGCG-UHFFFAOYSA-N 6-[7-(8-chloronaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-6-azabicyclo[3.2.1]octan-3-ol Chemical compound OC(CC(C1)C2)CC1N2C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(Cl)=C13)=C2F XFBCGMOPRHAGCG-UHFFFAOYSA-N 0.000 description 2
- OQMSJGHKRYWHIP-ICAILCLXSA-N 6-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-6-azabicyclo[3.2.1]octan-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CC(C3)C4)C3CC4O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F OQMSJGHKRYWHIP-ICAILCLXSA-N 0.000 description 2
- NJDSJRFGZNFQBE-UHFFFAOYSA-N 6-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-6-azabicyclo[3.2.1]octan-3-ol Chemical compound OC(CC(C1)C2)CC1N2C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F NJDSJRFGZNFQBE-UHFFFAOYSA-N 0.000 description 2
- ODIUJYZERXVGEI-UHFFFAOYSA-N 6-benzyl-3-pyridin-4-yl-5,8-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one Chemical compound O=C1Nc2cc3[nH]nc(-c4ccncc4)c3cc2CN1Cc1ccccc1 ODIUJYZERXVGEI-UHFFFAOYSA-N 0.000 description 2
- AHDYKJGBMVANTF-UHFFFAOYSA-N 8-[8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-4-(3-hydroxy-3-methylpiperidin-1-yl)pyrido[4,3-d]pyrimidin-7-yl]naphthalene-1-carbonitrile Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=C3C(C#N)=CC=CC3=CC=C1)=C2F)O AHDYKJGBMVANTF-UHFFFAOYSA-N 0.000 description 2
- JORYJLUSJWIDLO-UHFFFAOYSA-N 8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-4-(3-imidazol-1-ylazetidin-1-yl)pyrido[4,3-d]pyrimidine Chemical compound FC1=C2C(C(N=CC(C(N(C3)CC3N3C=NC=C3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 JORYJLUSJWIDLO-UHFFFAOYSA-N 0.000 description 2
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 229940126638 Akt inhibitor Drugs 0.000 description 2
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 229940080328 Arginase inhibitor Drugs 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- XVFDNRYZXDHTHT-PXAZEXFGSA-N BI-3406 Chemical compound COc1cc2nc(C)nc(N[C@H](C)c3cc(N)cc(c3)C(F)(F)F)c2cc1O[C@H]1CCOC1 XVFDNRYZXDHTHT-PXAZEXFGSA-N 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 2
- XWAFMPHFNJCVLG-UHFFFAOYSA-N CC(C)(C)C(OC(C1=C2C#C)=CC=CC1=CC=C2F)=O Chemical compound CC(C)(C)C(OC(C1=C2C#C)=CC=CC1=CC=C2F)=O XWAFMPHFNJCVLG-UHFFFAOYSA-N 0.000 description 2
- JCOIHUDSMNOMKD-LZSLTWNJSA-N CCC1=C2C(C(N=CC(C(N(CC[C@@H]3F)C[C@@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F Chemical compound CCC1=C2C(C(N=CC(C(N(CC[C@@H]3F)C[C@@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F JCOIHUDSMNOMKD-LZSLTWNJSA-N 0.000 description 2
- MWLFHDCHZWOXPL-BQDSYXTOSA-N CCC1=C2C(C(N=CC(C(N3CC(CS(N)(=O)=O)CCC3)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F Chemical compound CCC1=C2C(C(N=CC(C(N3CC(CS(N)(=O)=O)CCC3)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F MWLFHDCHZWOXPL-BQDSYXTOSA-N 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 2
- JQNINBDKGLWYMU-GEAQBIRJSA-N CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 Chemical compound CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 JQNINBDKGLWYMU-GEAQBIRJSA-N 0.000 description 2
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- YQQZZYYQTCPEAS-OYLFLEFRSA-N ClC=1C(=C(C=CC=1)CN1[C@@H](C[C@@](CC1)(C(=O)O)CC1=NC(=CC=C1F)NC1=NNC(=C1)C)C)F Chemical compound ClC=1C(=C(C=CC=1)CN1[C@@H](C[C@@](CC1)(C(=O)O)CC1=NC(=CC=C1F)NC1=NNC(=C1)C)C)F YQQZZYYQTCPEAS-OYLFLEFRSA-N 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- AZFNNMYFMTWDSQ-OYRHEFFESA-N FC1=C2C(C(N=CC(C(N3C[C@@H](CC4)C[C@@H]4C3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 Chemical compound FC1=C2C(C(N=CC(C(N3C[C@@H](CC4)C[C@@H]4C3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 AZFNNMYFMTWDSQ-OYRHEFFESA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- 102000009127 Glutaminase Human genes 0.000 description 2
- 108010073324 Glutaminase Proteins 0.000 description 2
- 229940121727 Glutaminase inhibitor Drugs 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229940124785 KRAS inhibitor Drugs 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 2
- HHCBMISMPSAZBF-UHFFFAOYSA-N LY3009120 Chemical compound CC1=NC2=NC(NC)=NC=C2C=C1C1=CC(NC(=O)NCCC(C)(C)C)=C(F)C=C1C HHCBMISMPSAZBF-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- SUDAHWBOROXANE-UHFFFAOYSA-N N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide Chemical compound OCC(O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-UHFFFAOYSA-N 0.000 description 2
- NBTNHSGBRGTFJS-UHFFFAOYSA-N N-(2,4-dimethoxyphenyl)-N-[2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]carbamic acid (2,6-dimethylphenyl) ester Chemical compound COC1=CC(OC)=CC=C1N(C=1N=C(NC=2C=CC(=CC=2)N2CCN(C)CC2)N=CC=1)C(=O)OC1=C(C)C=CC=C1C NBTNHSGBRGTFJS-UHFFFAOYSA-N 0.000 description 2
- MBWRLLRCTIYXDW-UHFFFAOYSA-N N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound ClC1=C(C(=C(C=C1OC)OC)Cl)NC(N(C)C1=CC(=NC=N1)NC1=C(C=C(C=C1)N1CCN(CC1)CC)NC(C=C)=O)=O MBWRLLRCTIYXDW-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229940126002 RMC-4630 Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108700022176 SOS1 Proteins 0.000 description 2
- 102000057028 SOS1 Human genes 0.000 description 2
- 229940126271 SOS1 inhibitor Drugs 0.000 description 2
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 2
- 101150100839 Sos1 gene Proteins 0.000 description 2
- MQMKRQLTIWPEDM-UHFFFAOYSA-N XL147 Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC2=NSN=C2C=C1 MQMKRQLTIWPEDM-UHFFFAOYSA-N 0.000 description 2
- QAJRFPVPHUYVFE-JGVFFNPUSA-N [(2S,8R)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methanol Chemical compound F[C@H]1C[C@]2(CCCN2C1)CO QAJRFPVPHUYVFE-JGVFFNPUSA-N 0.000 description 2
- AWIHHSCSGVBUNR-SFVRFVRKSA-N [(3R,5S)-5-[[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-[(3S)-3-hydroxy-3-methylpiperidin-1-yl]pyrido[4,3-d]pyrimidin-2-yl]oxymethyl]-1-methylpyrrolidin-3-yl] N-methylcarbamate Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@@]3(C)O)=N3)=C4N=C3OC[C@H](C3)N(C)C[C@@H]3OC(NC)=O)=C4F)=CC(O)=CC2=CC=C1F AWIHHSCSGVBUNR-SFVRFVRKSA-N 0.000 description 2
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 2
- MUJMYVFVAWFUJL-SNAWJCMRSA-O [(e)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium Chemical compound CN1C=NC([N+]([O-])=O)=C1C[N+](C)(C)C\C=C\C(=O)NC(N=CC1=NC=N2)=CC1=C2NC1=CC=C(Cl)C(Br)=C1 MUJMYVFVAWFUJL-SNAWJCMRSA-O 0.000 description 2
- OCYZABOUZSORIT-UHFFFAOYSA-N [1-[(dimethylamino)methyl]cyclopropyl]methanol Chemical compound CN(C)CC1(CO)CC1 OCYZABOUZSORIT-UHFFFAOYSA-N 0.000 description 2
- XXVKFRYOWKYNTM-UHFFFAOYSA-N [1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]azepan-3-yl]methanol Chemical compound OCC(CCCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F XXVKFRYOWKYNTM-UHFFFAOYSA-N 0.000 description 2
- YQEGMHZQIOHABT-UHFFFAOYSA-N [1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]methanol Chemical compound OCC(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F YQEGMHZQIOHABT-UHFFFAOYSA-N 0.000 description 2
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 description 2
- BEMNJULZEQTDJY-UHFFFAOYSA-N [5-amino-1-(2-methyl-3h-benzimidazol-5-yl)pyrazol-4-yl]-(1h-indol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)C=3C=NN(C=3N)C=3C=C4N=C(NC4=CC=3)C)=CC2=C1 BEMNJULZEQTDJY-UHFFFAOYSA-N 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 238000003016 alphascreen Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000012925 biological evaluation Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 2
- 235000008207 calcium folinate Nutrition 0.000 description 2
- 239000011687 calcium folinate Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- SFJMFSWCBVEHBA-UHFFFAOYSA-M copper(i)-thiophene-2-carboxylate Chemical compound [Cu+].[O-]C(=O)C1=CC=CS1 SFJMFSWCBVEHBA-UHFFFAOYSA-M 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 229950002205 dacomitinib Drugs 0.000 description 2
- 229950006418 dactolisib Drugs 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- BMTPVPNVQOYGAP-UHFFFAOYSA-N diethyl 6-methoxy-5,7-dihydroindolo[2,3-b]carbazole-2,10-dicarboxylate Chemical compound N1C2=CC=C(C(=O)OCC)C=C2C2=C1C(OC)=C1NC3=CC=C(C(=O)OCC)C=C3C1=C2 BMTPVPNVQOYGAP-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229950001969 encorafenib Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 2
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 2
- 229950009767 lifirafenib Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- BJTFTQIBRVBSBH-MUHQWPPJSA-N murizatoclax Chemical compound [H][C@]12CC[C@@H]1CN1C[C@@]3(CCCC4=CC(Cl)=CC=C34)COC3=C1C=C(C=C3)C(=O)NS(=O)(=O)[C@@H](C)[C@H](C)C\C=C\[C@@]2(CN1CCN2CCCC[C@]2([H])C1)OC BJTFTQIBRVBSBH-MUHQWPPJSA-N 0.000 description 2
- 229940071537 murizatoclax Drugs 0.000 description 2
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 description 2
- ZYQXEVJIFYIBHZ-UHFFFAOYSA-N n-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide Chemical compound C=12N(CCNC(=O)CC(C)(O)C)C=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 ZYQXEVJIFYIBHZ-UHFFFAOYSA-N 0.000 description 2
- ILUKRINUNLAVMH-UHFFFAOYSA-N n-[2-[[2-[(2-methoxy-5-methylpyridin-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-5-methylphenyl]prop-2-enamide Chemical compound C1=NC(OC)=CC(NC=2N=C(NC=3C(=CC(C)=CC=3)NC(=O)C=C)C(=CN=2)C(F)(F)F)=C1C ILUKRINUNLAVMH-UHFFFAOYSA-N 0.000 description 2
- UEPXBTCUIIGYCY-UHFFFAOYSA-N n-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide Chemical compound C1=C(C=2C=C(N=C(OCCO)C=2)N2CCOCC2)C(C)=CC=C1NC(=O)C1=CC=NC(C(F)(F)F)=C1 UEPXBTCUIIGYCY-UHFFFAOYSA-N 0.000 description 2
- TUYDDIWQXWTNSW-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 TUYDDIWQXWTNSW-UHFFFAOYSA-N 0.000 description 2
- IVUGFMLRJOCGAS-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine Chemical compound CC1=CSC(C=2C3=CC=CC=C3C(NC=3C=CC(OC=4C(=CC=CN=4)C=4N=C(N)N=CC=4)=CC=3)=NN=2)=C1 IVUGFMLRJOCGAS-UHFFFAOYSA-N 0.000 description 2
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960004390 palbociclib Drugs 0.000 description 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- RYYNGWLOYLRZLK-RBUKOAKNSA-N pf03814735 Chemical compound C1([C@H]2CC[C@@H](C1=CC=1)N2C(=O)CNC(=O)C)=CC=1NC(N=1)=NC=C(C(F)(F)F)C=1NC1CCC1 RYYNGWLOYLRZLK-RBUKOAKNSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229950004941 pictilisib Drugs 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 2
- 229960001131 ponatinib Drugs 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 230000003651 pro-proliferative effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108010077182 raf Kinases Proteins 0.000 description 2
- 102000009929 raf Kinases Human genes 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 2
- 229950006474 sapitinib Drugs 0.000 description 2
- 229950009919 saracatinib Drugs 0.000 description 2
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229940121497 sintilimab Drugs 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 229950007213 spartalizumab Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 229940020043 tapotoclax Drugs 0.000 description 2
- GMFUILAFZFPFJH-UHFFFAOYSA-N tert-butyl 5-oxo-3-azabicyclo[2.2.1]heptane-3-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1CC2=O GMFUILAFZFPFJH-UHFFFAOYSA-N 0.000 description 2
- XCBYSHPEYBCENP-UHFFFAOYSA-N tert-butyl 6-oxo-3,7-dihydro-2h-azepine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC=CC(=O)C1 XCBYSHPEYBCENP-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- YVIIZHMCFKPOND-QJCIYXEWSA-N (1R,5R,6R)-3-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[1-(pyrrolidin-1-ylmethyl)cyclopropyl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-azabicyclo[3.2.1]octan-6-ol Chemical compound CCC1=C2C(C(N=CC(C(N(C[C@H](C3)C4)C[C@@H]3[C@@H]4O)=N3)=C4N=C3OCC3(CN5CCCC5)CC3)=C4F)=CC(O)=CC2=CC=C1F YVIIZHMCFKPOND-QJCIYXEWSA-N 0.000 description 1
- KSOVGRCOLZZTPF-QMKUDKLTSA-N (1s,2s,3r,4r)-3-[[5-fluoro-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)F)=NC=1NC(C=C1C)=CC=C1N1CCN(C)CC1 KSOVGRCOLZZTPF-QMKUDKLTSA-N 0.000 description 1
- IYXUFOCLMOXQSL-UHFFFAOYSA-N (2,2-difluoroacetyl) 2,2-difluoroacetate Chemical compound FC(F)C(=O)OC(=O)C(F)F IYXUFOCLMOXQSL-UHFFFAOYSA-N 0.000 description 1
- BVRGQPJKSKKGIH-PUAOIOHZSA-N (2R)-2-[5-[5-chloro-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxo-1H-isoindol-2-yl]-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide Chemical compound ClC=1C(=NC(=NC=1)NC1CCOCC1)C1=CC=C2CN(C(C2=C1)=O)[C@@H](C(=O)N[C@H](CO)C1=CC(=CC(=C1)OC)F)C BVRGQPJKSKKGIH-PUAOIOHZSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GEEVVVFGEMYBOU-WLDISPQGSA-N (2R,8S)-8-[[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-[(3R)-3-hydroxy-3-methylpiperidin-1-yl]pyrido[4,3-d]pyrimidin-2-yl]oxymethyl]-1,2,3,5,6,7-hexahydropyrrolizin-2-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5O)=C4F)=CC(O)=CC2=CC=C1F GEEVVVFGEMYBOU-WLDISPQGSA-N 0.000 description 1
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- KGWWHPZQLVVAPT-STTJLUEPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(\C=C\C=2C=CC=CC=2)=N1 KGWWHPZQLVVAPT-STTJLUEPSA-N 0.000 description 1
- CHYFRYQQELBYSV-JGCGQSQUSA-N (3R)-1-[2-[3-(dimethylamino)-2,2-dimethylpropoxy]-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OCC(C)(C)CN(C)C)=C4F)=CC(O)=CC2=CC=C1F CHYFRYQQELBYSV-JGCGQSQUSA-N 0.000 description 1
- DJEDOGQVLHPHFI-HDRWKKCNSA-N (3R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(3R,8R)-3-(hydroxymethyl)-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OC[C@]3(CCC5)N5[C@@H](CO)CC3)=C4F)=CC(O)=CC2=CC=C1F DJEDOGQVLHPHFI-HDRWKKCNSA-N 0.000 description 1
- DJEDOGQVLHPHFI-JUIDXDJLSA-N (3R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(3S,8S)-3-(hydroxymethyl)-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OC[C@@]3(CCC5)N5[C@H](CO)CC3)=C4F)=CC(O)=CC2=CC=C1F DJEDOGQVLHPHFI-JUIDXDJLSA-N 0.000 description 1
- VLDYPAAMGUVPQP-MGBGTMOVSA-N (3R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[1-(morpholin-4-ylmethyl)cyclopropyl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)C[C@]3(C)O)=N3)=C4N=C3OCC3(CN5CCOCC5)CC3)=C4F)=CC(O)=CC2=CC=C1F VLDYPAAMGUVPQP-MGBGTMOVSA-N 0.000 description 1
- DTMZVVZTBUUOMZ-OPHVGKIYSA-N (3R,4S)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-4-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CC[C@@H]3C)C[C@@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F DTMZVVZTBUUOMZ-OPHVGKIYSA-N 0.000 description 1
- ZZJLMZYUGLJBSO-LAEOZQHASA-N (3R,4S)-3-amino-1-[(2S)-2-aminopropanoyl]-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid Chemical compound N[C@]1(CN(C[C@@H]1CCCB(O)O)C([C@H](C)N)=O)C(=O)O ZZJLMZYUGLJBSO-LAEOZQHASA-N 0.000 description 1
- DFTRGUHDUFPARY-IXIYYFDFSA-N (3R,5R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-5-methylpiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(C[C@H](C)C3)C[C@@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F DFTRGUHDUFPARY-IXIYYFDFSA-N 0.000 description 1
- VKEBTLJBGAWKOF-NWXPOEFQSA-N (3R,5S)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-5-fluoropiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(C[C@@H](C3)O)C[C@H]3F)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F VKEBTLJBGAWKOF-NWXPOEFQSA-N 0.000 description 1
- NFCWAHYNSYSOBI-VBKZILBWSA-N (3S,4S)-8-[7-(2,3-dichlorophenyl)-6-methylpyrazolo[1,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(-c3cccc(Cl)c3Cl)n3nccc23)[C@@H]1N NFCWAHYNSYSOBI-VBKZILBWSA-N 0.000 description 1
- DBZMLVHSKWQDAH-SUMWQHHRSA-N (3S,4S)-8-[7-(2-amino-3-chloropyridin-4-yl)sulfanyl-6-methylpyrazolo[1,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C1CN(CCC21[C@@H]([C@@H](OC2)C)N)C=1C=2N(N=CC=2)C(SC2=C(C(=NC=C2)N)Cl)=C(N=1)C DBZMLVHSKWQDAH-SUMWQHHRSA-N 0.000 description 1
- HBYKPCRKPMMTCE-YVEFUNNKSA-N (3S,4S)-8-[7-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazolo[1,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C1C2(CCN(CC2)C=2C=3N(N=CC=3)C(SC3=C(C(=NC=C3)N)Cl)=CN=2)[C@@H]([C@@H](O1)C)N HBYKPCRKPMMTCE-YVEFUNNKSA-N 0.000 description 1
- IBBBJPZHEOQDOD-INOGPEIASA-N (3S,6R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]azepane-3,6-diol Chemical compound CCC1=C2C(C(N=CC(C(N(C[C@@H](CC3)O)C[C@H]3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F IBBBJPZHEOQDOD-INOGPEIASA-N 0.000 description 1
- YYACLQUDUDXAPA-MRXNPFEDSA-N (3r)-n-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide Chemical compound C1[C@H](F)CCN1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=NC(=NC=2)C2CC2)=C1F YYACLQUDUDXAPA-MRXNPFEDSA-N 0.000 description 1
- LOGJQOUIVKBFGH-YBEGLDIGSA-N (3z)-n,n-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1h-indol-2-ylmethylidene)-2,3-dihydro-1h-indole-5-sulfonamide Chemical compound C1CCCC(N2)=C1C=C2\C=C1/C(=O)NC2=CC=C(S(=O)(=O)N(C)C)C=C21 LOGJQOUIVKBFGH-YBEGLDIGSA-N 0.000 description 1
- FQRWAOBIGYQJCW-GOSISDBHSA-N (4R)-8-[6-(2,3-dichlorophenyl)-5-methylpyridin-3-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound ClC1=C(C=CC=C1Cl)C1=C(C=C(C=N1)N1CCC2(CCC[C@H]2N)CC1)C FQRWAOBIGYQJCW-GOSISDBHSA-N 0.000 description 1
- DCBTYRHXIPKPJJ-GOSISDBHSA-N (4R)-8-[6-(2,3-dichlorophenyl)sulfanyl-5-methylpyridin-3-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound ClC1=C(C=CC=C1Cl)SC1=C(C=C(C=N1)N1CCC2([C@@H](CCC2)N)CC1)C DCBTYRHXIPKPJJ-GOSISDBHSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BVOCPVIXARZNQN-RXMQYKEDSA-N (R)-nipecotamide Chemical compound NC(=O)[C@@H]1CCCNC1 BVOCPVIXARZNQN-RXMQYKEDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LAXRNWSASWOFOT-UHFFFAOYSA-J (cymene)ruthenium dichloride dimer Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Ru+2].[Ru+2].CC(C)C1=CC=C(C)C=C1.CC(C)C1=CC=C(C)C=C1 LAXRNWSASWOFOT-UHFFFAOYSA-J 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical group C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical group C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical group C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- PLAVWQHGBMTMFR-UHFFFAOYSA-N 1-(2,3-dichlorobenzoyl)-4-[[5-fluoro-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridin-2-yl]methyl]piperidine-4-carboxylic acid Chemical compound N1C(C)=CC(NC=2C(=CC=C(CC3(CCN(CC3)C(=O)C=3C(=C(Cl)C=CC=3)Cl)C(O)=O)N=2)F)=N1 PLAVWQHGBMTMFR-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- RZUOCXOYPYGSKL-GOSISDBHSA-N 1-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one Chemical compound CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C=3C=C(F)C(Cl)=CC=3)C=C2)=N1 RZUOCXOYPYGSKL-GOSISDBHSA-N 0.000 description 1
- GEHZIZWHNLQFAS-OAHLLOKOSA-N 1-[(2R)-4-[6-[[2-[4-(3,3-difluorocyclobutyl)oxy-6-methylpyridin-2-yl]acetyl]amino]pyridazin-3-yl]-2-fluorobutyl]-N-methyltriazole-4-carboxamide Chemical compound CNC(=O)C1=CN(C[C@H](F)CCC2=CC=C(NC(=O)CC3=NC(C)=CC(OC4CC(F)(F)C4)=C3)N=N2)N=N1 GEHZIZWHNLQFAS-OAHLLOKOSA-N 0.000 description 1
- KEIPNCCJPRMIAX-HNNXBMFYSA-N 1-[(3s)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C#CC=2C3=C(N)N=CN=C3N([C@@H]3CN(CC3)C(=O)C=C)N=2)=C1 KEIPNCCJPRMIAX-HNNXBMFYSA-N 0.000 description 1
- YCHACHBXEKFOBZ-UHFFFAOYSA-N 1-[2-[[1-[(dimethylamino)methyl]cyclopropyl]methoxy]-8-fluoro-7-(8-fluoronaphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CN(C)C)CC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F)O YCHACHBXEKFOBZ-UHFFFAOYSA-N 0.000 description 1
- DVVSLINCVKKMAI-UHFFFAOYSA-N 1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)cyclohexyl]-9-quinolin-3-ylbenzo[h][1,6]naphthyridin-2-one Chemical compound CCC(=O)N1CCN(CC1)C2CCC(CC2C(F)(F)F)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6 DVVSLINCVKKMAI-UHFFFAOYSA-N 0.000 description 1
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 description 1
- VOENNMYVIQADCN-IFXJQAMLSA-N 1-[4-[5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)-3-methylpyrazin-2-yl]sulfanyl-3-chloropyridin-2-yl]azetidin-3-ol Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=NC(C)=C(SC3=C(Cl)C(=NC=C3)N3CC(O)C3)N=C2CO)[C@@H]1N VOENNMYVIQADCN-IFXJQAMLSA-N 0.000 description 1
- FVUWZHPOFUDRKZ-UHFFFAOYSA-N 1-[5-(2,3-dichlorophenyl)-6-methylimidazo[1,5-a]pyrazin-8-yl]-4-methylpiperidin-4-amine Chemical compound CC1=C(N2C=NC=C2C(=N1)N1CCC(C)(N)CC1)C1=C(Cl)C(Cl)=CC=C1 FVUWZHPOFUDRKZ-UHFFFAOYSA-N 0.000 description 1
- IMOCEIBJDUUYQV-UHEVQHBQSA-N 1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-4,4-difluoropiperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3(F)F)CC3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F IMOCEIBJDUUYQV-UHEVQHBQSA-N 0.000 description 1
- CBGCCIJEJANXND-ZDKWMYCKSA-N 1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]azepan-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCCC3)CC3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F CBGCCIJEJANXND-ZDKWMYCKSA-N 0.000 description 1
- DALZRLVOYLOQPS-FEMKAPKCSA-N 1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)CC3O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F DALZRLVOYLOQPS-FEMKAPKCSA-N 0.000 description 1
- OBKYEAJJGPGPEK-UHFFFAOYSA-N 1-[8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-7-(5-hydroxy-2-methylphenyl)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=C(C)C=CC(O)=C1)=C2F)O OBKYEAJJGPGPEK-UHFFFAOYSA-N 0.000 description 1
- QPPFKULBDHCAAI-UHFFFAOYSA-N 1-[8-fluoro-7-(2-fluoro-5-hydroxyphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol Chemical compound CC(CCC1)(CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C(C=C(C=C1)O)=C1F)=C2F)O QPPFKULBDHCAAI-UHFFFAOYSA-N 0.000 description 1
- CRWRCEMYRYBLKW-UHFFFAOYSA-N 1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-N-methylpiperidine-3-sulfonamide Chemical compound CNS(C(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F)(=O)=O CRWRCEMYRYBLKW-UHFFFAOYSA-N 0.000 description 1
- OVWSFXNSJDMRPV-UHFFFAOYSA-N 1-benzylpiperidin-3-one;hydron;chloride Chemical compound Cl.C1C(=O)CCCN1CC1=CC=CC=C1 OVWSFXNSJDMRPV-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- KBQCEQAXHPIRTF-UHFFFAOYSA-N 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(36),4(38),6,11,14,16,18,20,23,29(37),30,32,34-tridecaene-23-carboxylic acid Chemical compound CN1N=C2CSCC3=NN(C)C(CSC4=CC(OCCCC5=C(N(C)C6=C5C=CC(Cl)=C6C2=C1C)C(O)=O)=C1C=CC=CC1=C4)=C3 KBQCEQAXHPIRTF-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical group C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- NYGFDSVWTYZHQM-UHFFFAOYSA-N 2-(2-bromo-3,4-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(F)=C1Br NYGFDSVWTYZHQM-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- VUZDAGDVJPWBNM-UHFFFAOYSA-N 2-[1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]-1,2-thiazolidine 1,1-dioxide Chemical compound O=S(CCC1)(N1C(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F)=O VUZDAGDVJPWBNM-UHFFFAOYSA-N 0.000 description 1
- QHCGPJPIPKDWAT-UHFFFAOYSA-N 2-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-6-(4-methylpiperazin-1-yl)-1H-benzimidazole Chemical compound COC1=CC(OC)=CC(CCC2=CC(=NN2)C2=NC3=C(N2)C=CC(=C3)N2CCN(C)CC2)=C1 QHCGPJPIPKDWAT-UHFFFAOYSA-N 0.000 description 1
- PKYIMGFMRFVOMB-UHFFFAOYSA-N 2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid Chemical compound ClC=1C(=C(C=CC=1OCCN1CCN(CC1)C)C1=C(SC=2N=CN=C(C=21)OC(C(=O)O)CC1=C(C=CC=C1)OCC1=NC(=NC=C1)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)F)C PKYIMGFMRFVOMB-UHFFFAOYSA-N 0.000 description 1
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HNNUBQWDWJNURV-UHFFFAOYSA-N 2-bromoethynyl-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)C#CBr HNNUBQWDWJNURV-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- HDXDQPRPFRKGKZ-INIZCTEOSA-N 3-(3-fluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)propyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3NC=NC=3N=CN=2)CC)OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HDXDQPRPFRKGKZ-INIZCTEOSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- DZQXOICEPZPDBU-AGMZAMARSA-N 3-[7-(8-bromo-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-azabicyclo[3.2.1]octan-6-ol Chemical compound OC(CC(C1)C2)C1CN2C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C(C1=C3Br)=CC(O)=CC1=CC=C3F)=C2F DZQXOICEPZPDBU-AGMZAMARSA-N 0.000 description 1
- FILCTHZWKHLGMN-AGMZAMARSA-N 3-[7-(8-chloro-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-azabicyclo[3.2.1]octan-6-ol Chemical compound OC(CC(C1)C2)C1CN2C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C(C1=C3Cl)=CC(O)=CC1=CC=C3F)=C2F FILCTHZWKHLGMN-AGMZAMARSA-N 0.000 description 1
- VAQXNSIHNOIPOM-UHFFFAOYSA-N 3-[7-(8-ethylnaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3-azabicyclo[3.2.1]octan-6-ol Chemical compound CCC1=C2C(C(N=CC(C(N(CC(C3)C4)CC3C4O)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 VAQXNSIHNOIPOM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RDXDQJARPYHCMD-UHFFFAOYSA-N 3-methoxy-3-methylpiperidine Chemical compound COC1(C)CCCNC1 RDXDQJARPYHCMD-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 description 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical group CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 description 1
- SEWJDVAURXHWMC-UHFFFAOYSA-N 5-(4-amino-4-methylpiperidin-1-yl)-2-(2,3-dichlorophenyl)-6-(hydroxymethyl)pyridin-3-ol Chemical compound CC1(N)CCN(CC1)c1cc(O)c(nc1CO)-c1cccc(Cl)c1Cl SEWJDVAURXHWMC-UHFFFAOYSA-N 0.000 description 1
- AOQKKJHIPNWTHL-UHFFFAOYSA-N 5-(4-amino-4-methylpiperidin-1-yl)-2-(2,3-dichlorophenyl)sulfanylpyridin-3-ol Chemical compound NC1(CCN(CC1)C=1C=C(C(=NC=1)SC1=C(C(=CC=C1)Cl)Cl)O)C AOQKKJHIPNWTHL-UHFFFAOYSA-N 0.000 description 1
- QYBGBLQCOOISAR-UHFFFAOYSA-N 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine Chemical compound N1=C2N(C(C)C)C(C)=NC2=C(C=2C=NC(N)=NC=2)N=C1N1CCOCC1 QYBGBLQCOOISAR-UHFFFAOYSA-N 0.000 description 1
- YDYPDKPBOWMOAZ-FKIZINRSSA-N 5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-2-(2,3-dichlorophenyl)-6-(hydroxymethyl)pyridin-3-ol Chemical compound C[C@@H]1OCC2(CCN(CC2)c2cc(O)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N YDYPDKPBOWMOAZ-FKIZINRSSA-N 0.000 description 1
- XCKMOSWVWSEHGK-GOSISDBHSA-N 5-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-2-(2,3-dichlorophenyl)-6-(hydroxymethyl)pyridin-3-ol Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1C=C(C(=NC=1CO)C1=C(C(=CC=C1)Cl)Cl)O XCKMOSWVWSEHGK-GOSISDBHSA-N 0.000 description 1
- ICDFYPLIFBICSQ-QGZVFWFLSA-N 5-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-2-(2,3-dichlorophenyl)pyridin-3-ol Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1C=C(C(=NC=1)C1=C(C(=CC=C1)Cl)Cl)O ICDFYPLIFBICSQ-QGZVFWFLSA-N 0.000 description 1
- KDEGOSVQAQCTIC-QGZVFWFLSA-N 5-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-2-(2,3-dichlorophenyl)sulfanylpyridin-3-ol Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1C=C(C(=NC=1)SC1=C(C(=CC=C1)Cl)Cl)O KDEGOSVQAQCTIC-QGZVFWFLSA-N 0.000 description 1
- LZZYEMSEMRUPIM-UHFFFAOYSA-N 5-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-n-(2-morpholin-4-ylethyl)-1,3,4-oxadiazol-2-amine Chemical compound C=1C=C(I)C=C(F)C=1NC1=C(F)C(F)=CC=C1C(O1)=NN=C1NCCN1CCOCC1 LZZYEMSEMRUPIM-UHFFFAOYSA-N 0.000 description 1
- QLAOMAQKOKJIAV-UHFFFAOYSA-N 5-[7-(3-chloro-2-cyclopropyl-5-hydroxyphenyl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3a,4,6,6a-tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione Chemical compound OC1=CC(C(N=CC(C(N(CC2C(N3)=O)CC2C3=O)=N2)=C3N=C2OCC2(CCC4)N4CCC2)=C3F)=C(C2CC2)C(Cl)=C1 QLAOMAQKOKJIAV-UHFFFAOYSA-N 0.000 description 1
- NNTZJHDDMOQTHI-FTSDHYKSSA-N 5-[7-(8-bromo-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3a,4,6,6a-tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione Chemical compound OC(C=C(C1=C2Br)C(N=CC(C(N(CC3C(N4)=O)CC3C4=O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC1=CC=C2F NNTZJHDDMOQTHI-FTSDHYKSSA-N 0.000 description 1
- UIAAYTWYLGOWRA-FTSDHYKSSA-N 5-[7-(8-chloro-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3a,4,6,6a-tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione Chemical compound OC(C=C(C1=C2Cl)C(N=CC(C(N(CC3C(N4)=O)CC3C4=O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC1=CC=C2F UIAAYTWYLGOWRA-FTSDHYKSSA-N 0.000 description 1
- UKRSPAQFOKPZFV-UHFFFAOYSA-N 5-[7-(8-ethylnaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3a,4,6,6a-tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione Chemical compound CCC1=C2C(C(N=CC(C(N(CC3C(N4)=O)CC3C4=O)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 UKRSPAQFOKPZFV-UHFFFAOYSA-N 0.000 description 1
- XOIKNUXMCXTWPB-UHFFFAOYSA-N 5-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-N,N-dimethyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-2-carboxamide Chemical compound CN(C)C(N1N=C(CCCN(C2)C3=NC(OCC4(CCC5)N5CCC4)=NC4=C3C=NC(C3=CC=CC5=CC=CC(F)=C35)=C4F)C2=C1)=O XOIKNUXMCXTWPB-UHFFFAOYSA-N 0.000 description 1
- CQMGNSJGJWCBJI-UHFFFAOYSA-N 5-chloro-6-fluoro-3,4-dihydro-2H-naphthalen-1-one Chemical compound O=C1CCCC2=C(Cl)C(F)=CC=C21 CQMGNSJGJWCBJI-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 description 1
- ULDPIELKOFRZGQ-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine dihydrochloride Chemical compound Cl.Cl.CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl ULDPIELKOFRZGQ-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- BLQYVHBZHAISJM-CMDGGOBGSA-N 6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC=2NN=C(C)C=2)=NC(\C=C\C=2C=CC=CC=2)=N1 BLQYVHBZHAISJM-CMDGGOBGSA-N 0.000 description 1
- QIEKHLDZKRQLLN-FOIQADDNSA-N 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@](CCC1)(C)O)F QIEKHLDZKRQLLN-FOIQADDNSA-N 0.000 description 1
- OONFNUWBHFSNBT-FQEVSTJZSA-N 6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-n-[(1s)-1-phenylethyl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-FQEVSTJZSA-N 0.000 description 1
- SLRCQDVTLWOQRG-NJCWVQCSSA-N 6-[7-(8-bromo-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-6-azabicyclo[3.2.1]octan-3-ol Chemical compound OC(CC(C1)C2)CC1N2C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C(C1=C3Br)=CC(O)=CC1=CC=C3F)=C2F SLRCQDVTLWOQRG-NJCWVQCSSA-N 0.000 description 1
- NBQXXRQKYPYPOP-NJCWVQCSSA-N 6-[7-(8-chloro-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-6-azabicyclo[3.2.1]octan-3-ol Chemical compound OC(CC(C1)C2)CC1N2C1=NC(OC[C@](CCC2)(C3)N2C[C@@H]3F)=NC2=C1C=NC(C(C1=C3Cl)=CC(O)=CC1=CC=C3F)=C2F NBQXXRQKYPYPOP-NJCWVQCSSA-N 0.000 description 1
- YGLKSGCODJMCRO-ICAILCLXSA-N 6-[7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-6-azabicyclo[3.2.1]octan-3-ol Chemical compound C#CC1=C2C(C(N=CC(C(N(CC(C3)C4)C3CC4O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F YGLKSGCODJMCRO-ICAILCLXSA-N 0.000 description 1
- PKFZAHRBTXNTSA-UHFFFAOYSA-N 6-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-5,7,8,9-tetrahydropyrido[3,2-c]azepine Chemical compound FC1=C2C(C(N=CC(C(N(CCC3)CC4=C3N=CC=C4)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 PKFZAHRBTXNTSA-UHFFFAOYSA-N 0.000 description 1
- DOCINCLJNAXZQF-LBPRGKRZSA-N 6-fluoro-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 DOCINCLJNAXZQF-LBPRGKRZSA-N 0.000 description 1
- RHCMVBJGOIOJGA-FEMKAPKCSA-N 7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-4-[3-(sulfamoylamino)piperidin-1-yl]pyrido[4,3-d]pyrimidine Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)CC3NS(N)(=O)=O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F RHCMVBJGOIOJGA-FEMKAPKCSA-N 0.000 description 1
- GXLAGDIPTJXHLW-UHFFFAOYSA-N 7-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-4,4a,5,6,8,8a-hexahydro-2,7-naphthyridine-1,3-dione Chemical compound O=C(CC(CC1)C2CN1C1=NC(OCC3(CCC4)N4CCC3)=NC3=C1C=NC(C1=CC=CC4=CC=CC(F)=C14)=C3F)NC2=O GXLAGDIPTJXHLW-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- BFANNCFXNHKKTC-UHFFFAOYSA-N 7-fluoronaphthalen-1-ol Chemical compound C1=C(F)C=C2C(O)=CC=CC2=C1 BFANNCFXNHKKTC-UHFFFAOYSA-N 0.000 description 1
- FBRWVUWBHWKVEH-UHFFFAOYSA-N 8-[(2-methylpropan-2-yl)oxycarbonyl]-8-azabicyclo[3.2.1]octane-4-carboxylic acid Chemical compound C1CC(C(O)=O)C2CCC1N2C(=O)OC(C)(C)C FBRWVUWBHWKVEH-UHFFFAOYSA-N 0.000 description 1
- MPTOEZHOSZIEJY-UHFFFAOYSA-N 8-[8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-4-[3-(1H-1,2,4-triazol-5-yl)piperidin-1-yl]pyrido[4,3-d]pyrimidin-7-yl]naphthalene-1-carbonitrile Chemical compound N#CC1=CC=CC2=CC=CC(C(N=CC(C(N(CCC3)CC3C3=NNC=N3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=C12 MPTOEZHOSZIEJY-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- XUNODCLRHITXPV-UHFFFAOYSA-N 8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-7-(8-methylnaphthalen-1-yl)-4-[3-(1H-1,2,4-triazol-5-yl)piperidin-1-yl]pyrido[4,3-d]pyrimidine Chemical compound CC1=C2C(C(N=CC(C(N(CCC3)CC3C3=NNC=N3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 XUNODCLRHITXPV-UHFFFAOYSA-N 0.000 description 1
- VMQNHVFACJDWBI-UHFFFAOYSA-N 8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-4-(3-pyridin-4-ylazetidin-1-yl)pyrido[4,3-d]pyrimidine Chemical compound FC1=C2C(C(N=CC(C(N(C3)CC3C3=CC=NC=C3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 VMQNHVFACJDWBI-UHFFFAOYSA-N 0.000 description 1
- DCVIZGIQWIWNIG-UHFFFAOYSA-N 8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-4-[3-(1,2,4-triazol-1-yl)azetidin-1-yl]pyrido[4,3-d]pyrimidine Chemical compound FC1=C2C(C(N=CC(C(N(C3)CC3N3N=CN=C3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 DCVIZGIQWIWNIG-UHFFFAOYSA-N 0.000 description 1
- WDHAAJIGSXNPFO-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CN=C2NC(=O)C=CC2=C1 WDHAAJIGSXNPFO-UHFFFAOYSA-N 0.000 description 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
- 229960005531 AMG 319 Drugs 0.000 description 1
- 101150019464 ARAF gene Proteins 0.000 description 1
- 229940126287 ASP5878 Drugs 0.000 description 1
- 229940126113 ASTX029 Drugs 0.000 description 1
- 238000012815 AlphaLISA Methods 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000272878 Apodiformes Species 0.000 description 1
- 229960005523 BI 811283 Drugs 0.000 description 1
- 229940125795 BI-3406 Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MTEKFVQXJXBQSY-UHFFFAOYSA-N CC(C)[Si](C(C)C)(C(C)C)OC(C1=C2F)=CC(O)=CC1=CC=C2F Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC(C1=C2F)=CC(O)=CC1=CC=C2F MTEKFVQXJXBQSY-UHFFFAOYSA-N 0.000 description 1
- FDQQKMOYPATNSD-QLNOICANSA-N CCC1=C2C(C(N=CC(C(N(CCC3)CC3N(CCC3)S3(=O)=O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F Chemical compound CCC1=C2C(C(N=CC(C(N(CCC3)CC3N(CCC3)S3(=O)=O)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F FDQQKMOYPATNSD-QLNOICANSA-N 0.000 description 1
- BJUSFNPWGSLLMK-KBXCAEBGSA-N CO[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=C(CO)N=C(C(C)=N1)C1=CC=CC(Cl)=C1Cl Chemical compound CO[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=C(CO)N=C(C(C)=N1)C1=CC=CC(Cl)=C1Cl BJUSFNPWGSLLMK-KBXCAEBGSA-N 0.000 description 1
- BUOUORLMWPVUJS-MUUNZHRXSA-N C[C@@](CCC1)(CN1C1=NC(OCC2(CN(C)C)CC2)=NC2=C1C=NC(C1=C(C3CC3)C(Cl)=CC(O)=C1)=C2F)O Chemical compound C[C@@](CCC1)(CN1C1=NC(OCC2(CN(C)C)CC2)=NC2=C1C=NC(C1=C(C3CC3)C(Cl)=CC(O)=C1)=C2F)O BUOUORLMWPVUJS-MUUNZHRXSA-N 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- YWPHBSHEGTZPNS-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)C)C=1CCN(CC=1)C1CCOCC1)OC(C)C)NC1=C(C=CC=C1)S(=O)(=O)C(C)C Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)C)C=1CCN(CC=1)C1CCOCC1)OC(C)C)NC1=C(C=CC=C1)S(=O)(=O)C(C)C YWPHBSHEGTZPNS-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- HVVNJUAVDAZWCB-RXMQYKEDSA-N D-prolinol Chemical compound OC[C@H]1CCCN1 HVVNJUAVDAZWCB-RXMQYKEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical group C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 229940124640 MK-2206 Drugs 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 description 1
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 1
- UPNLLXYRYREPHL-UHFFFAOYSA-N N-[1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]formamide Chemical compound O=CNC(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F UPNLLXYRYREPHL-UHFFFAOYSA-N 0.000 description 1
- LHAPKZJWSVRRPG-UHFFFAOYSA-N N-[1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-4-yl]formamide Chemical compound O=CNC(CC1)CCN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F LHAPKZJWSVRRPG-UHFFFAOYSA-N 0.000 description 1
- YUGCEVMUDKEBPY-UHFFFAOYSA-N N-[3-[5-(2-cyclopropylpyrimidin-5-yl)-3a,7a-dihydro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide Chemical compound C1(CC1)C1=NC=C(C=N1)C1=CC2C(N=C1)NC=C2C(=O)C=1C(=C(C=CC=1F)NS(=O)(=O)N1CC(CC1)F)F YUGCEVMUDKEBPY-UHFFFAOYSA-N 0.000 description 1
- MNNXRVSQOABRRP-UHFFFAOYSA-N N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-4-thiazolyl]-4-quinazolinamine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 MNNXRVSQOABRRP-UHFFFAOYSA-N 0.000 description 1
- GCIKSSRWRFVXBI-UHFFFAOYSA-N N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GCIKSSRWRFVXBI-UHFFFAOYSA-N 0.000 description 1
- XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MZDKLVOWGIOKTN-UHFFFAOYSA-N N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]methanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=NC=CC=C1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F MZDKLVOWGIOKTN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940126682 ONC201 Drugs 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 229940125999 RMC-4550 Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- LOGJQOUIVKBFGH-UHFFFAOYSA-N SU6656 Chemical compound C1CCCC(N2)=C1C=C2C=C1C(=O)NC2=CC=C(S(=O)(=O)N(C)C)C=C21 LOGJQOUIVKBFGH-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000038008 SrcA subfamily Human genes 0.000 description 1
- 108091008119 SrcA subfamily Proteins 0.000 description 1
- 108091008116 SrcB subfamily Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 description 1
- 229940125811 TNO155 Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- HJSSPYJVWLTYHG-UHFFFAOYSA-N XL765 Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC(NC(=O)C=3C=C(OC)C(C)=CC=3)=CC=2)=C1 HJSSPYJVWLTYHG-UHFFFAOYSA-N 0.000 description 1
- MCSMAEKVMQAPIQ-FHAQVOQBSA-N [(2s,4s)-4-fluoropyrrolidin-2-yl]methanol;hydrochloride Chemical compound Cl.OC[C@@H]1C[C@H](F)CN1 MCSMAEKVMQAPIQ-FHAQVOQBSA-N 0.000 description 1
- OBYFJFMLUXZLTN-UHFFFAOYSA-N [1-[7-(8-chloronaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]methanesulfonamide Chemical compound NS(CC(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(Cl)=C13)=C2F)(=O)=O OBYFJFMLUXZLTN-UHFFFAOYSA-N 0.000 description 1
- IFTNLSMCEDQHFN-UHFFFAOYSA-N [1-[7-(8-ethylnaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]methanesulfonamide Chemical compound CCC1=C2C(C(N=CC(C(N3CC(CS(N)(=O)=O)CCC3)=N3)=C4N=C3OCC3(CCC5)N5CCC3)=C4F)=CC=CC2=CC=C1 IFTNLSMCEDQHFN-UHFFFAOYSA-N 0.000 description 1
- QXUYCSHKUZCJES-UHFFFAOYSA-N [1-[8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-7-[8-(hydroxymethyl)naphthalen-1-yl]pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]methanesulfonamide Chemical compound NS(CC(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(CO)=C13)=C2F)(=O)=O QXUYCSHKUZCJES-UHFFFAOYSA-N 0.000 description 1
- UVPVXHSLMJOHFD-UHFFFAOYSA-N [1-[8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)-7-naphthalen-1-ylpyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]methanesulfonamide Chemical compound NS(CC(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC=C13)=C2F)(=O)=O UVPVXHSLMJOHFD-UHFFFAOYSA-N 0.000 description 1
- QIKVIEULWFABPA-BFPHTYPKSA-N [1-[8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7-(7-fluoro-3-hydroxy-8-methylnaphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]methanesulfonamide Chemical compound CC1=C2C(C(N=CC(C(N3CC(CS(N)(=O)=O)CCC3)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F QIKVIEULWFABPA-BFPHTYPKSA-N 0.000 description 1
- UNWQDTDDSCAKOL-UHFFFAOYSA-N [1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]urea Chemical compound NC(NC(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F)=O UNWQDTDDSCAKOL-UHFFFAOYSA-N 0.000 description 1
- UNPKUGJRBIHKBC-UHFFFAOYSA-N [1-[8-fluoro-7-(8-fluoronaphthalen-1-yl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-4-yl]urea Chemical compound NC(NC(CC1)CCN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(F)=C13)=C2F)=O UNPKUGJRBIHKBC-UHFFFAOYSA-N 0.000 description 1
- LWHFPOSXZXFUOE-UHFFFAOYSA-N [1-[8-fluoro-7-[8-(fluoromethyl)naphthalen-1-yl]-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]piperidin-3-yl]methanesulfonamide Chemical compound NS(CC(CCC1)CN1C1=NC(OCC2(CCC3)N3CCC2)=NC2=C1C=NC(C1=CC=CC3=CC=CC(CF)=C13)=C2F)(=O)=O LWHFPOSXZXFUOE-UHFFFAOYSA-N 0.000 description 1
- BCOFSUKABXOTCS-VBKZILBWSA-N [2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyridin-3-yl]methanol Chemical compound C1C2(CCN(CC2)C2=C(CO)C=C(C3=CC=CC(Cl)=C3Cl)C(C)=N2)[C@@H]([C@@H](O1)C)N BCOFSUKABXOTCS-VBKZILBWSA-N 0.000 description 1
- AUPXBVDHVRZMIB-GXXYEPOPSA-M [2H]C([2H])([2H])[Mg]I Chemical compound [2H]C([2H])([2H])[Mg]I AUPXBVDHVRZMIB-GXXYEPOPSA-M 0.000 description 1
- HEBAUXVSCHILOZ-UHFFFAOYSA-N [3-(4-amino-4-methylpiperidin-1-yl)-6-(2,3-dichlorophenyl)-5-methylpyridin-2-yl]methanol Chemical compound NC1(CCN(CC1)C=1C(=NC(=C(C=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C HEBAUXVSCHILOZ-UHFFFAOYSA-N 0.000 description 1
- ISUZFGREBXYQCS-LHSJRXKWSA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyridin-2-yl]methanol Chemical compound C[C@@H]1OCC2(CCN(CC2)c2cc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N ISUZFGREBXYQCS-LHSJRXKWSA-N 0.000 description 1
- MPUKZLNIWCKIEK-SCLBCKFNSA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)sulfanyl-5-methylpyrazin-2-yl]methanol Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=C(CO)N=C(SC3=CC=CC(Cl)=C3Cl)C(C)=N2)[C@@H]1N MPUKZLNIWCKIEK-SCLBCKFNSA-N 0.000 description 1
- QICYDNZCTVLYOT-LJQANCHMSA-N [3-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyridin-2-yl]methanol Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1C(=NC(=C(C=1)C)C1=C(C(=CC=C1)Cl)Cl)CO QICYDNZCTVLYOT-LJQANCHMSA-N 0.000 description 1
- RMOUUYCZCVEKQN-LJQANCHMSA-N [3-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)sulfanyl-5-methylpyridin-2-yl]methanol Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1C(=NC(=C(C=1)C)SC1=C(C(=CC=C1)Cl)Cl)CO RMOUUYCZCVEKQN-LJQANCHMSA-N 0.000 description 1
- INBQYRBJOZTLHU-LHSJRXKWSA-N [4-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-7-(2,3-dichlorophenyl)-6-methylpyrazolo[1,5-a]pyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C=2N(C(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)N=C(C=2)CO)C INBQYRBJOZTLHU-LHSJRXKWSA-N 0.000 description 1
- FJBOFZUMTCMCTF-SCLBCKFNSA-N [5-(2-amino-3-chloropyridin-4-yl)sulfanyl-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-methylpyridin-3-yl]methanol Chemical compound C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(Sc3ccnc(N)c3Cl)cc2CO)[C@@H]1N FJBOFZUMTCMCTF-SCLBCKFNSA-N 0.000 description 1
- MWJMQFBFFLMZQC-UHFFFAOYSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]methanol Chemical compound C1N(CCC(N)(C)C1)C1=C(N=C(SC2=C(C(=NC=C2)N)Cl)C=C1)CO MWJMQFBFFLMZQC-UHFFFAOYSA-N 0.000 description 1
- HMKBWZZAIVJCBI-SCLBCKFNSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyridin-2-yl]methanol Chemical compound C[C@@H]1OCC2(CCN(CC2)c2cc(C)c(Sc3ccnc(N)c3Cl)nc2CO)[C@@H]1N HMKBWZZAIVJCBI-SCLBCKFNSA-N 0.000 description 1
- JSNGJXYDEPKQBN-SCLBCKFNSA-N [7-(2-amino-3-chloropyridin-4-yl)sulfanyl-4-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-methylpyrazolo[1,5-a]pyrazin-2-yl]methanol Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=NC(C)=C(SC3=C(Cl)C(N)=NC=C3)N3N=C(CO)C=C23)[C@@H]1N JSNGJXYDEPKQBN-SCLBCKFNSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 229950001655 acalisib Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229950000079 afuresertib Drugs 0.000 description 1
- 229950009447 alisertib Drugs 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical group C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- LKLWTLXTOVZFAE-UHFFFAOYSA-N benzenesulfonic acid;n-methyl-n-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.CS(=O)(=O)N(C)C1=NC=CC=C1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F LKLWTLXTOVZFAE-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 229950002826 canertinib Drugs 0.000 description 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
- 229950009671 capivasertib Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229950002352 cenisertib Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229950002550 copanlisib Drugs 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 229950002966 danusertib Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940121432 dostarlimab Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940121446 futibatinib Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229950006331 ipatasertib Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 description 1
- 229960002293 leucovorin calcium Drugs 0.000 description 1
- 229950001762 linsitinib Drugs 0.000 description 1
- PKCDDUHJAFVJJB-VLZXCDOPSA-N linsitinib Chemical compound C1[C@](C)(O)C[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PKCDDUHJAFVJJB-VLZXCDOPSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CDRSBPYJKRZQAY-UHFFFAOYSA-N methyl morpholine-4-carboxylate Chemical compound COC(=O)N1CCOCC1 CDRSBPYJKRZQAY-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- UPJSUQWHUVLLNW-XMMPIXPASA-N n-(3-aminopropyl)-n-[(1r)-1-(3-anilino-7-chloro-4-oxoquinazolin-2-yl)but-3-ynyl]-3-chloro-2-fluorobenzamide Chemical compound C1([C@@H](CC#C)N(CCCN)C(=O)C=2C(=C(Cl)C=CC=2)F)=NC2=CC(Cl)=CC=C2C(=O)N1NC1=CC=CC=C1 UPJSUQWHUVLLNW-XMMPIXPASA-N 0.000 description 1
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 description 1
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 description 1
- PGTXVGREXBMCCY-UHFFFAOYSA-N n-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-4-(2-methylsulfonylbenzimidazol-1-yl)-6-morpholin-4-yl-1,3,5-triazin-2-amine Chemical compound C1CN(C)CCC1C1=CC=CC=C1CC(C)(C)NC1=NC(N2CCOCC2)=NC(N2C3=CC=CC=C3N=C2S(C)(=O)=O)=N1 PGTXVGREXBMCCY-UHFFFAOYSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- ZAJXXUDARPGGOC-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C)(C)C#CC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C ZAJXXUDARPGGOC-UHFFFAOYSA-N 0.000 description 1
- GTWJVFFZCKODEV-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.C1CN(C)CCN1C(C)(C)C#CC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C GTWJVFFZCKODEV-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- HHCSNTXVZDWIGT-CMDGGOBGSA-N n-[5-[[4-(2-hydroxyacetyl)piperazin-1-yl]methyl]-2-[(e)-2-(1h-indazol-3-yl)ethenyl]phenyl]-3-methylthiophene-2-carboxamide Chemical compound C1=CSC(C(=O)NC=2C(=CC=C(CN3CCN(CC3)C(=O)CO)C=2)\C=C\C=2C3=CC=CC=C3NN=2)=C1C HHCSNTXVZDWIGT-CMDGGOBGSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JWAZRIHNYRIHIV-DOMIDYPGSA-N naphthalen-2-ol Chemical compound C1=CC=[14CH]C2=CC(O)=CC=C21 JWAZRIHNYRIHIV-DOMIDYPGSA-N 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 229940015645 numidargistat Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical group C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical group C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 229940121317 pemigatinib Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950002592 pimasertib Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229950009876 poziotinib Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- GQIXFHWAAHPMSO-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=C=C[N]1 GQIXFHWAAHPMSO-UHFFFAOYSA-N 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Chemical group C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229950007231 ravoxertinib Drugs 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- BUROJSBIWGDYCN-QHPXJTPRSA-N ridaforolimus Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-QHPXJTPRSA-N 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- 229950009216 sapanisertib Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 1
- 229950008344 serabelisib Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229950007865 sonolisib Drugs 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950001269 taselisib Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- PRAAPINBUWJLGA-UHFFFAOYSA-N telaglenastat Chemical compound FC(F)(F)OC1=CC=CC(CC(=O)NC=2N=NC(CCCCC=3SC(NC(=O)CC=4N=CC=CC=4)=NN=3)=CC=2)=C1 PRAAPINBUWJLGA-UHFFFAOYSA-N 0.000 description 1
- 229940121507 telaglenastat Drugs 0.000 description 1
- 229950008214 tenalisib Drugs 0.000 description 1
- XUNAYZIHVQJKGX-UHFFFAOYSA-N tert-butyl 2,3,6,7-tetrahydroazepine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC=CCC1 XUNAYZIHVQJKGX-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- SCSMCZJZQYDACU-SNVBAGLBSA-N tert-butyl-dimethyl-[[(2r)-pyrrolidin-2-yl]methoxy]silane Chemical compound CC(C)(C)[Si](C)(C)OC[C@H]1CCCN1 SCSMCZJZQYDACU-SNVBAGLBSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- AKCRNFFTGXBONI-UHFFFAOYSA-N torin 1 Chemical compound C1CN(C(=O)CC)CCN1C1=CC=C(N2C(C=CC3=C2C2=CC(=CC=C2N=C3)C=2C=C3C=CC=CC3=NC=2)=O)C=C1C(F)(F)F AKCRNFFTGXBONI-UHFFFAOYSA-N 0.000 description 1
- 229940121514 toripalimab Drugs 0.000 description 1
- 229950000185 tozasertib Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 229950007127 trilaciclib Drugs 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229950008878 ulixertinib Drugs 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229940121344 umbralisib Drugs 0.000 description 1
- 229950005787 uprosertib Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229950006605 varlitinib Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229950007259 vistusertib Drugs 0.000 description 1
- 229950001576 voxtalisib Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- KIZNQHOVHYLYHY-UHFFFAOYSA-M zinc;prop-1-ene;bromide Chemical compound [Zn+2].[Br-].[CH2-]C=C KIZNQHOVHYLYHY-UHFFFAOYSA-M 0.000 description 1
- CGTADGCBEXYWNE-GTTQIJKGSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-GTTQIJKGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- HETEROCYCLIC COMPOUNDS AND METHODS OF USE CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63/231,543, filed August 10, 2021 and U.S. Provisional Patent Application No. 63/289,579, filed December 14, 2021, each of which is incorporated by reference in its entirety.
- FIELD The present disclosure provides compounds having activity as inhibitors of G12D mutant KRAS protein.
- This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to Non-Small Cell Lung Cancer (NSCLC), colorectal cancer and/or pancreatic cancer.
- NSCLC Non-Small Cell Lung Cancer
- KRAS the Kirsten rat sarcoma viral oncogene homologue
- KRAS protein has historically proven resistant to direct inhibition.
- KRAS is a G-protein that couples extracellular mitogenic signaling to intracellular, pro-proliferative responses.
- KRAS serves as an intracellular “on/off” switch. Mitogen stimulation induces the binding of GTP to KRAS, bringing about a conformational change which enables the interaction of KRAS with downstream effector proteins, leading to cellular proliferation.
- GAPs GTPase- activating proteins
- a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable excipient.
- a compound of Formula I, or a pharmaceutically acceptable salt of said compound, or the pharmaceutical composition as described herein for use in treating cancer e.g., NSCLC, colorectal cancer or pancreatic cancer.
- embodiment 2 is the compound according to embodiment 1, wherein L is C 1-6 alkylene (e.g., methylene or ethylene) substituted with 0-2 occurrences of R 2 .
- embodiment 3 is the compound according to embodiment 1, wherein L is -O-C 1-6 alkylene (e.g., -O-methylene-, -O-ethylene- or -O-n-propylene) substituted with 0-2 occurrences of R 2 .
- embodiment 4 is the compound according to embodiment 3, wherein L is -O-ethylene or -O-n-propylene substituted with 0-2 occurrences of R 2 .
- embodiment 5 is the compound according to embodiment 4, wherein L is -O-ethylene substituted with 0 occurrences of R 2 .
- embodiment 6 is the compound according to any one of embodiments 1-5, wherein R 1 is heterocycloalkyl substituted with 0-3 occurrences of R 5 .
- embodiment 7 is the compound according to embodiment 6, wherein R 1 is 7-(hexahydro-1H-pyrrolizine) substituted with 0-3 occurrences of R 5 .
- embodiment 8 is the compound according to embodiment 7, wherein R 1 is 7-(hexahydro-1H- pyrrolizine) substituted with 0 occurrences of R 5 .
- embodiment 9 is the compound according to embodiment 7, wherein R 1 is 7-(hexahydro-1H-pyrrolizine) substituted with 1 occurrence of R 5 .
- embodiment 10 is the compound according to embodiment 9, wherein R 5 is halogen (e.g., fluorine).
- embodiment 11 is the compound according to embodiment 6, wherein R 1 is 2-pyrrolidine or 3-pyrrolidine substituted with 0-3 occurrences of R 5 .
- embodiment 12 is the compound according to embodiment 11, wherein R 1 is 3- pyrrolidine substituted with 1 occurrence of R 5 .
- embodiment 13 is the compound according to embodiment 12, wherein R 5 is cyano.
- embodiment 14 is the compound according to embodiment 11, wherein R 1 is 3-pyrrolidine substituted with 2 occurrences of R 5 .
- embodiment 15 is the compound according to embodiment 14, wherein one R 5 is methyl and the other R 5 is cyano.
- embodiment 16 is the compound according to embodiment 11, wherein R 1 is 2-pyrrolidine substituted with 2 occurrences of R 5 .
- embodiment 17 is the compound according to embodiment 16, wherein R 5 is C 1-4 alkyl (e.g., methyl), oxo, cyano or halogen (e.g., fluorine).
- embodiment 18 is the compound according to embodiment 16, wherein one R 5 is methyl and the other R 5 is fluorine.
- embodiment 19 is the compound according to embodiment 16, wherein one R 5 is methyl and the other R 5 is oxo.
- embodiment 20 is the compound according to embodiment 3, wherein L is -O-n-propylene substituted with 2 occurrences of R 2 .
- embodiment 21 is the compound according to embodiment 20, wherein the two R 2 are taken together with the same carbon atom to form a C 3-7 cycloalkyl (e.g., cyclopropyl).
- embodiment 22 is the compound according to embodiment 21, wherein R 1 is heterocycloalkyl (e.g., N-morpholinyl) substituted with 0-3 occurrences of R 5 .
- embodiment 23 is the compound according to embodiment 21, wherein R 1 is hydroxyl.
- embodiment 24 is the compound according to any one of embodiments 1-23, wherein - , , , , Provided herein as embodiment 25 is the compound according to embodiment 24, r .
- Provided herein as embodiment 26 is the compound according to embodiment 24, wherein -L-R 1 is .
- Provided herein as embodiment 27 is the compound according to embodiment 24, wherein - .
- embodiment 28 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 29 is the compound according to embodiment 24, wherein -L .
- embodiment 30 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 31 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 32 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 33 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 34 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 35 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 36 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 37 is the compound according to embodiment 24, wherein -L-R 1 is .
- embodiment 38 is the compound according to any one of embodiments 1-37, wherein R 3 is aryl (e.g., phenyl or naphthyl) substituted with 0-3 occurrences of R 6 .
- embodiment 39 is the compound according to any one of embodiments 1-37, wherein R 3 is naphthyl substituted with 1 occurrence of R 6 .
- embodiment 40 is the compound according to embodiment 39, wherein R 6 is halogen, amino, C 1-4 alkyl (e.g., methyl), C 1-4 haloalkyl (e.g., trifluoromethyl or difluoromethyl), hydroxyl or C 2-4 alkynyl (e.g., ethynyl).
- R 6 is halogen, amino, C 1-4 alkyl (e.g., methyl), C 1-4 haloalkyl (e.g., trifluoromethyl or difluoromethyl), hydroxyl or C 2-4 alkynyl (e.g., ethynyl).
- embodiment 41 is the compound according to embodiment 40, wherein R 6 is hydroxyl.
- embodiment 42 is the compound according to embodiment 38, wherein R 3 is naphthyl substituted with 2 occurrences of R 6 .
- embodiment 43 is the compound according to embodiment 42, wherein R 6 is C 1-4 alkyl, C 2-4 alkynyl, C 3-6 cycloalkyl, halogen, hydroxyl or -N(R z ) 2 .
- embodiment 44 is the compound according to embodiment 43, wherein R 6 is ethyl, ethynyl, cyclopropyl, fluorine, chlorine, hydroxyl or -NH 2 .
- embodiment 45 is the compound according to embodiment 43, wherein one R 6 is ethynyl and the other R 6 is hydroxyl.
- embodiment 46 is the compound according to embodiment 43, wherein one R 6 is ethyl and the other R 6 is hydroxyl.
- embodiment 47 is the compound according to embodiment 43, wherein one R 6 is ethyl and the other R 6 is fluorine.
- embodiment 48 is the compound according to embodiment 43, wherein both R 6 are fluorine.
- embodiment 49 is the compound according to embodiment 43, wherein one R 6 is cyclopropyl and the other R 6 is hydroxyl.
- embodiment 50 is the compound according to embodiment 43, wherein one R 6 is fluorine and the other R 6 is hydroxyl.
- embodiment 51 is the compound according to embodiment 43, wherein one R 6 is chlorine and the other R 6 is -NH 2 .
- embodiment 52 is the compound according to embodiment 43, wherein one R 6 is ethynyl and the other R 6 is fluorine.
- embodiment 53 is the compound according to embodiment 38, wherein R 3 is naphthyl substituted with 3 occurrences of R 6 .
- embodiment 54 is the compound according to embodiment 53, wherein R 6 is C 1-4 alkyl, C 2-4 alkynyl, halogen or hydroxyl.
- embodiment 55 is the compound according to embodiment 54, wherein R 6 is ethyl, ethynyl, fluorine or hydroxyl.
- embodiment 56 is the compound according to embodiment 54, wherein one R 6 is hydroxyl, another R 6 is ethyl and the final R 6 is fluorine.
- embodiment 57 is the compound according to embodiment 54, wherein one R 6 is hydroxyl, another R 6 is ethynyl and the final R 6 is fluorine.
- embodiment 58 is the compound according to embodiment 54, wherein two R 6 are halogen (e.g., fluorine or chlorine) and the other R 6 is hydroxy.
- embodiment 59 is the compound according to embodiment 38, wherein R 3 is phenyl substituted with 3 occurrences of R 6 .
- embodiment 60 is the compound according to embodiment 59, wherein one R 6 is hydroxyl, another R 6 is cyclopropyl and the final R 6 is chlorine.
- embodiment 61 is the compound according to any one of embodiments 1-37, wherein R 3 is heteroaryl (e.g., 4-(1H-indazole) or 4-benzo[d]thiazolyl) substituted with 0-3 occurrences of R 6 .
- embodiment 62 is the compound according to embodiment 61, wherein R 3 is 4-(1H-indazole) substituted with 2 occurrences of R 6 .
- embodiment 63 is the compound according to embodiment 62, wherein one R 6 is methyl and the other R 6 is chlorine.
- embodiment 64 is the compound according to embodiment 61, wherein R 3 is 4-benzo[d]thiazolyl substituted with 2 occurrences of R 6 .
- embodiment 65 is the compound according to embodiment 64, wherein one R 6 is fluorine and the other R 6 is -NH 2 .
- embodiment 66 is the compound according to any one of embodiments 1-65, wherein R 3 is Provided herein as embodiment 67 is the compound according to embodiment 66, wherein R 3 is .
- embodiment 68 is the compound according to embodiment 66, wherein R 3 is .
- embodiment 69 is the compound according to embodiment 66, wherein R 3 is .
- embodiment 70 is the compound according to embodiment 66, wherein .
- embodiment 71 is the compound according to embodiment 66, wherein R 3 is .
- embodiment 72 is the compound according to embodiment 66, wherein R 3 is .
- embodiment 73 is the compound according to embodiment 66, wherein R 3 - 12 - is .
- embodiment 74 is the compound according to embodiment 66, wherein R 3 is .
- embodiment 75 is the compound according to embodiment 66, wherein R 3 is Provided herein as embodiment 76 is the compound according to embodiment 66, wherein R 3 i .
- embodiment 77 is the compound according to embodiment 66, wherein R 3 is Provided herein as embodiment 78 is the compound according to embodiment 66, wherein R 3 is Provided herein as embodiment 79 is the compound according to embodiment 66, wherein R 3 is Provided herein as embodiment 80 is the compound according to embodiment 66, wherein Provided herein as embodiment 81 is the compound according to embodiment 66, wherein .
- embodiment 82 is the compound according to embodiment 66, wherein .
- embodiment 83 is the compound according to embodiment 66, wherein R 3 is .
- embodiment 84 is the compound according to any one of embodiments 1-83, wherein W is N and --- is a single bond.
- embodiment 85 is the compound according to any one of embodiments 1-84, wherein X is CH 2 .
- embodiment 86 is the compound according to embodiment 85, wherein n is 0 and m is 0.
- embodiment 87 is the compound according to embodiment 86, wherein p is 1.
- embodiment 88 is the compound according to embodiment 87, wherein R x is 5-7 membered heteroaryl or -T-R y .
- embodiment 89 is the compound according to embodiment 87, wherein R x is 5-7 membered heteroaryl substituted with 0-3 occurrences of R y .
- embodiment 90 is the compound according to embodiment 89, wherein R x is 1-imidazolyl substituted with 0 occurrences of R y .
- embodiment 91 is the compound according to embodiment 89, wherein -T-R y is -CH 2 OH, -C(O)NH 2 , -CH 2 C(O)NH 2 , -CH 2 S(O) 2 NH 2 or - S(O) 2 NH 2 .
- embodiment 92 is the compound according to embodiment 86, wherein p is 2.
- embodiment 93 is the compound according to embodiment 92, wherein each R x is hydroxyl, C 1-4 alkyl, -T-R y or two R x taken together with adjacent carbon atoms form 5-7 membered heterocycloalkyl substituted with 0-3 occurrences of R y .
- embodiment 94 is the compound according to embodiment 93, wherein one R x is methyl and the other R x is hydroxyl.
- embodiment 95 is the compound according to embodiment 93, wherein one R x is -C(O)NH 2 and the other R x is hydroxyl.
- embodiment 96 is the compound according to embodiment 92, wherein two R x taken together with adjacent carbon atoms form a 1-tetrahydrofuranyl or 2- tetrahydrofuranyl substituted with 0 occurrences of R y .
- embodiment 97 is the compound according to embodiment 86, wherein n is 1 and m is 0 or when n is 0 and m is 1.
- embodiment 98 is the compound according to embodiment 97, wherein p is 0.
- embodiment 99 is the compound according to embodiment 97, wherein p is 1.
- embodiment 100 is the compound according to embodiment 99, wherein R x is hydroxyl or -T-R y .
- embodiment 101 is the compound according to embodiment 100, wherein R x -T-R y is -CH 2 OH, -CH 2 S(O) 2 NH 2 , -C(O)NH 2 or -S(O) 2 NH 2 .
- embodiment 102 is the compound according to embodiment 97, wherein p is 2.
- embodiment 103 is the compound according to embodiment 102, wherein R x is hydroxyl, halogen, -T-R y or two R x are taken together with adjacent carbon atoms form a C 3-7 cycloalkyl or 5-7 membered heterocycloalkyl wherein each cycloalkyl or heterocycloalkyl is substituted with 0-3 occurrences of R y .
- embodiment 104 is the compound according to embodiment 103, wherein both R x are hydroxyl.
- embodiment 105 is the compound according to embodiment 103, wherein one R x is fluorine and the other is -CH 2 OH.
- embodiment 106 is the compound according to embodiment 102, wherein two R x taken together with adjacent carbon atoms form a C 3-7 cycloalkyl or a 5-7 membered heterocycloalkyl substituted with 0-3 occurrences of R y .
- embodiment 107 is the compound according to embodiment 106, wherein two R x taken together with adjacent carbon atoms form a cyclobutyl substituted with one occurrence of R y .
- embodiment 108 is the compound according to embodiment 107, wherein R y is hydroxyl.
- embodiment 109 is the compound according to embodiment 106, wherein two R x taken together with adjacent carbon atoms form a 1-tetrahydrofuranyl or 2-tetrahydrofuranyl substituted with 0 occurrences of R y .
- embodiment 110 is the compound according to any one of e r .
- embodiment 111 is the compound according to embodiment 110, w .
- embodiment 112 is the compound according to embodiment 110, wherein .
- embodiment 113 is the compound according to embodiment 110, wherein
- embodiment 114 is the compound according to embodiment 110, wherein .
- embodiment 115 is the compound according to embodiment 110, wherein .
- embodiment 116 is the compound according to embodiment 110, wherein .
- embodiment 117 is the compound according to embodiment 110, wherein is .
- embodiment 118 is the compound according to embodiment 110, wherein .
- embodiment 119 is the compound according to embodiment 110, wherein .
- embodiment 120 is the compound according to embodiment 110, wherein Provided herein as embodiment 121 is the compound according to embodiment 110, wherein .
- embodiment 122 is the compound according to embodiment 110, wherein is .
- embodiment 123 is the compound according to embodiment 110, wherein .
- embodiment 124 is the compound according to embodiment 110, wherein is .
- embodiment 125 is the compound according to embodiment 110, wherein .
- embodiment 126 is the compound according to embodiment 110, wherein is Provided herein as embodiment 127 is the compound according to embodiment 110, wherein s embodiment 128 is the compound according to embodiment 110, wherein is .
- embodiment 129 is the compound according to embodiment 110, wherein .
- embodiment 130 is the compound according to embodiment 110, wherein s .
- embodiment 131 is the compound according to embodiment 110, wherein .
- embodiment 132 is the compound according to embodiment 110, wherein .
- embodiment 133 is the compound according to embodiment 110, wherein Provided herein as embodiment 134 is the compound according to embodiment 85, wherein n is 1 and m is 1.
- embodiment 135 is the compound according to embodiment 134, wherein p is 0.
- embodiment 136 is the compound according to embodiment 134, wherein p is 1.
- embodiment 137 is the compound according to embodiment 136, wherein R x is hydroxyl, cyano, C 1-4 alkoxy, -N(R z ) 2 , 5-7 membered heteroaryl or -T-R y .
- embodiment 138 is the compound according to embodiment 136, wherein R x is hydroxyl, cyano, methoxy, -NH 2 , 5-oxazolyl, 4-imidazolyl or 3-pyrazolyl.
- embodiment 139 is the compound according to embodiment 137, wherein -T-R y is -NHC(O)OMe, -S(O) 2 Me, -NHC(O)Me, -NHC(O)-N(H)CH 2 CH 2 OMe, -CH 2 OH, -NHS(O) 2 Me, -CO 2 H, -C(O) 2 Me, 1-isopropanol, -S(O) 2 NH 2 , -C(O)NH 2 , -S(O) 2 N(H)Me or -C(O)N(H)Me.
- embodiment 140 is the compound according to embodiment 134, wherein p is 2.
- embodiment 141 is the compound according to embodiment 140, wherein R x is halogen, hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 3-7 cycloalkyl, -N(R z ) 2 or -T-R y or two R x taken together with the same carbon atom form a 5-7 membered heterocycloalkyl substituted with 0-3 occurrences of R y .
- embodiment 142 is the compound according to embodiment 141, wherein one R x is fluorine and one R x is hydroxyl.
- embodiment 143 is the compound according to embodiment 141, wherein one R x is methyl and one R x is hydroxyl.
- embodiment 144 is the compound according to embodiment 141, wherein one R x is -NHS(O) 2 Me and one R x is methyl.
- embodiment 145 is the compound according to embodiment 141, wherein one R x is -C(O)NH 2 and one R x is hydroxyl.
- embodiment 146 is the compound according to embodiment 141, wherein one R x is methoxy and one R x is methyl.
- embodiment 147 is the compound according to embodiment 141, wherein one R x is -NH 2 and one R x is methyl.
- embodiment 148 is the compound according to embodiment 141, wherein one R x is -NHC(O)OMe and one R x is methyl.
- embodiment 149 is the compound according to embodiment 141, wherein one R x is cyclopropyl and one R x is hydroxyl.
- embodiment 150 is the compound according to embodiment 141, wherein one R x is trifluoromethyl and one R x is hydroxyl.
- embodiment 151 is the compound according to embodiment 141, wherein one R x is difluoromethyl and one R x is hydroxyl.
- embodiment 152 is the compound according to embodiment 141, wherein one R x is -C(O)NH 2 and one R x is methyl.
- embodiment 153 is the compound according to embodiment 141, wherein one R x is -CH 2 OH and one R x is chloromethyl.
- embodiment 154 is the compound according to embodiment 141, wherein both R x are hydroxyl.
- embodiment 155 is the compound according to embodiment 140, wherein two R x are taken together with adjacent carbon atoms form a 5-7 membered heterocycloalkyl substituted with 0-3 occurrences of R y .
- embodiment 156 is the compound according to embodiment 155, wherein two R x are taken together with adjacent carbon atoms to form 1-tetrahydrofuranyl substituted with 0 occurrences of R y .
- embodiment 157 is the compound according to embodiment 155, wherein two R x are taken together with adjacent carbon atoms to form 1-pyrrolidinyl or 2-pyrrolidinyl substituted with 1 occurrence of R y .
- embodiment 158 is the compound according to embodiment 157, wherein R y is oxo.
- embodiment 159 is the compound according to embodiment 134, wherein p is 3.
- embodiment 160 is the compound according to embodiment 159, wherein one R x is hydroxyl, halogen, oxo, C 1-4 alkyl or two R x taken together with adjacent carbon atoms can form C 3-7 cycloalkyl substituted with 0-3 occurrences of R y or two R x taken together can form a bridged ring further substituted with 0- 2 occurrences of R y .
- embodiment 161 is the compound according to embodiment 160, wherein one R x is hydroxyl and the other two R x are methyl.
- embodiment 162 is the compound according to embodiment 160, wherein one R x is hydroxyl and the other two R x are fluorine.
- embodiment 163 is the compound according to embodiment 160, wherein one R x is -C(O)NH 2 and the other two R x are methyl.
- embodiment 164 is the compound according to embodiment 160, wherein one R x is oxo and the other two R x are fluorine.
- embodiment 165 is the compound according to embodiment 160, wherein one R x is hydroxyl and the other two R x taken together with adjacent carbon atoms form cyclopropyl substituted with 0 occurrences of R y .
- embodiment 166 is the compound according to embodiment 160, wherein one R x is hydroxyl and the other two R x taken together form an ethylene or methylene bridge substituted with 0 occurrences of R y .
- embodiment 167 is the compound according to embodiment 160, wherein one R x is C(O)NH 2 and the other two R x taken together form an ethylene substituted with 0 occurrences of R y .
- embodiment 168 is the compound according to any one of ,
- embodiment 169 is the compound according to embodiment 168, wherein .
- embodiment 170 is the compound according to embodiment 168, wherein .
- d herein as embodiment 171 is the compound according to embodiment 168, wherein .
- embodiment 172 is the compound according to embodiment 168, wherein .
- embodiment 173 is the compound according to embodiment 168, wherein is mbodiment 174 is the compound according to embodiment 168, wherein .
- embodiment 175 is the compound according to embodiment 168, wherein .
- embodiment 176 is the compound according to embodiment 168, wherein .
- embodiment 177 is the compound according to embodiment 168, wherein .
- embodiment 178 is the compound according to embodiment 168, wherein .
- embodiment 179 is the compound according to embodiment 168, wherein is .
- embodiment 180 is the compound according to embodiment 168, wherein Provided herein as embodiment 181 is the compound according to embodiment 168, wherein .
- embodiment 182 is the compound according to embodiment 168, wherein .
- embodiment 183 is the compound according to embodiment 168, wherein .
- embodiment 184 is the compound according to embodiment 168, wherein .
- embodiment 185 is the compound according to embodiment 168, wherein .
- embodiment 186 is the compound according to embodiment 168, wherein .
- embodiment 187 is the compound according to embodiment 168, wherein .
- embodiment 188 is the compound according to embodiment 168, wherein Provided herein as embodiment 189 is the compound according to embodiment 168, wherein .
- embodiment 190 is the compound according to embodiment 168, wherein .
- embodiment 191 is the compound according to embodiment 168, wherein .
- embodiment 192 is the compound according to embodiment 168, wherein .
- embodiment 193 is the compound according to embodiment 168, wherein .
- embodiment 194 is the compound according to embodiment 168, wherein .
- embodiment 195 is the compound according to embodiment 168, wherein .
- embodiment 196 is the compound according to embodiment 168, wherein is Provided herein as embodiment 197 is the compound according to embodiment 168, wherein .
- embodiment 198 is the compound according to embodiment 168, wherein is .
- embodiment 199 is the compound according to embodiment 168, wherein .
- embodiment 200 is the compound according to embodiment 168, wherein is .
- embodiment 201 is the compound according to embodiment 168, wherein Provided herein as embodiment 202 is the compound according to embodiment 168, wherein .
- Provided herein as embodiment 203 is the compound according to embodiment 168, wherein Provided herein as embodiment 204 is the compound according to embodiment 168, wherein .
- embodiment 205 is the compound according to embodiment 168, wherein .
- embodiment 206 is the compound according to embodiment 168, wherein .
- embodiment 207 is the compound according to embodiment 168, wherein .
- embodiment 208 is the compound according to embodiment 168, wherein .
- Provided herein as embodiment 209 is the compound according to embodiment 168, wherein Provided herein as embodiment 210 is the compound according to embodiment 168, wherein .
- embodiment 211 is the compound according to embodiment 168, wherein is .
- embodiment 212 is the compound according to embodiment 168, wherein .
- Provided herein as embodiment 213 is the compound according to embodiment 168, wherein is .
- embodiment 214 is the compound according to embodiment 168, wherein .
- embodiment 215 is the compound according to embodiment 168, wherein is Provided herein as embodiment 216 is the compound according to embodiment 168, wherein .
- embodiment 217 is the compound according to embodiment 168, wherein is .
- embodiment 218 is the compound according to embodiment 168, wherein .
- embodiment 219 is the compound according to embodiment 168, wherein is .
- embodiment 220 is the compound according to embodiment 168, wherein .
- embodiment 221 is the compound according to embodiment 168, wherein s Provided herein as embodiment 222 is the compound according to embodiment 1 Provided herein as embodiment 223 is the compound according to embodiment 168, wherein .
- Provided herein as embodiment 224 is the compound according to embodiment 168, wherein .
- Provided herein as embodiment 225 is the compound according to embodiment 168, wherein .
- Provided herein as embodiment 226 is the compound according to embodiment 168, wherein .
- Provided herein as embodiment 227 is the compound according to embodiment 168, wherein .
- Provided herein as embodiment 228 is the compound according to embodiment 168, wherein Provided herein as embodiment 229 is the compound according to embodiment 168, wherein .
- embodiment 230 is the compound according to embodiment 168, wherein .
- embodiment 231 is the compound according to embodiment 168, wherein .
- embodiment 232 is the compound according to embodiment 168, wherein is .
- embodiment 233 is the compound according to embodiment 168, wherein .
- embodiment 234 is the compound according to embodiment 168, wherein is Provided herein as embodiment 235 is the compound according to embodiment 168, wherein .
- embodiment 236 is the compound according to embodiment 168, wherein is Provided herein as embodiment 237 is the compound according to embodiment 168, wherein .
- embodiment 238 is the compound according to embodiment 168, wherein s .
- embodiment 239 is the compound according to embodiment 168, wherein .
- embodiment 240 is the compound according to embodiment 85, wherein n is 1 and m is 2 or n is 2 and m is 1.
- embodiment 241 is the compound according to embodiment 240, wherein p is 0.
- embodiment 242 is the compound according to embodiment 420, wherein p is 1.
- embodiment 243 is the compound according to embodiment 242, wherein R x is C 1-4 alkyl, C 1-4 alkenyl, cyano, hydroxyl, oxo, -N(R z ) 2 or -T-R y .
- embodiment 244 is the compound according to embodiment 243, wherein R x is cyano, methyl, oxo, hydroxyl, -NH 2 , methenyl, -SO 2 NH 2 , -NHC(O)Me or -NHC(O)CF 2 H.
- embodiment 245 is the compound according to embodiment 240, wherein p is 2.
- embodiment 246 is the compound according to embodiment 245, wherein R x is hydroxy, C 1-4 alkyl, halogen or two R x are taken together to form a C 1-4 alkylene bridged ring further substituted with 0-2 occurrences of R y .
- embodiment 247 is the compound according to embodiment 246, wherein both R x are fluorine.
- embodiment 248 is the compound according to embodiment 246, wherein one R x is hydroxyl and the other R x is methyl.
- embodiment 249 is the compound according to embodiment 246, wherein two R x are taken together to form a bridged ring wherein the bridge is methylene further substituted with 0 occurrences of R y .
- embodiment 250 is the compound according to embodiment 246, wherein two R x are taken together to form a bridged ring wherein the bridge is methylene further substituted with one occurrence of R y .
- embodiment 251 is the compound according to embodiment 250, wherein R y is hydroxyl.
- embodiment 252 is the compound according to embodiment 246, wherein two R x are taken together to form a bridged ring wherein the bridge is methylene further substituted with 2 occurrences of R y .
- embodiment 253 is the compound according to embodiment 252, wherein each R y is methyl or hydroxyl.
- embodiment 254 is the compound according to embodiment 240, wherein p is 3.
- embodiment 255 is the compound according to embodiment 254, wherein R x is hydroxy, oxo, halogen or two R x are taken together to form a C 1-4 alkylene bridged ring further substituted with 0-2 occurrences of R y .
- embodiment 256 is the compound according to embodiment 255, wherein one R x is oxo and the other two R x are fluorine.
- embodiment 257 is the compound according to embodiment 255, wherein one R x is hydroxyl and the other two R x are fluorine.
- embodiment 258 is the compound according to embodiment 255, wherein one R x is hydroxy and the other two R x are taken together to form a bridged ring wherein the bridge is methylene further substituted with 0 occurrences of R y .
- embodiment 259 is the compound according to embodiment 85, wherein n is 2 and m is 2.
- embodiment 260 is the compound according to embodiment 259, wherein p is 0.
- embodiment 261 is the compound according to embodiment 259, wherein p is 2.
- embodiment 262 is the compound according to embodiment 261, wherein two R x are taken together to form a bridged ring wherein the bridge is -O-.
- embodiment 263 is the compound according to any one of , .
- embodiment 264 is the compound according to embodiment 263, wherein Provided herein as embodiment 265 is the compound according to embodiment 263, wherein .
- embodiment 266 is the compound according to embodiment 263, wherein is .
- embodiment 267 is the compound according to embodiment 263, wherein .
- embodiment 268 is the compound according to embodiment 263, wherein .
- embodiment 269 is the compound according to embodiment 263, wherein .
- embodiment 270 is the compound according to embodiment 263, wherein .
- embodiment 271 is the compound according to embodiment 263, wherein Provided herein as embodiment 272 is the compound according to embodiment 263, wherein .
- embodiment 273 is the compound according to embodiment 263, wherein .
- embodiment 274 is the compound according to embodiment 263, wherein .
- embodiment 275 is the compound according to embodiment 263, wherein .
- embodiment 276 is the compound according to embodiment 263, wherein .
- embodiment 277 is the compound according to embodiment 263, wherein .
- embodiment 278 is the compound according to embodiment 263, wherein .
- embodiment 279 is the compound according to embodiment 263, wherein is Provided herein as embodiment 280 is the compound according to embodiment 263, wherein .
- embodiment 281 is the compound according to embodiment 263, wherein .
- embodiment 282 is the compound according to embodiment 263, wherein .
- embodiment 283 is the compound according to embodiment 263, wherein .
- embodiment 284 is the compound according to embodiment 263, wherein is Provided herein as embodiment 285 is the compound according to embodiment 263, wherein Provided herein as embodiment 286 is the compound according to embodiment 263, wherein d herein as embodiment 287 is the compound according to embodiment 263, wherein .
- embodiment 288 is the compound according to embodiment 263, wherein .
- embodiment 289 is the compound according to embodiment 263, wherein is .
- embodiment 290 is the compound according to embodiment 263, wherein .
- embodiment 291 is the compound according to embodiment 263, wherein .
- embodiment 292 is the compound according to embodiment 263, wherein
- embodiment 293 is the compound according to embodiment 263, wherein .
- embodiment 294 is the compound according to embodiment 263, wherein is .
- embodiment 296 is the compound according to embodiment 295, wherein n is 0 and m is 1.
- embodiment 297 is the compound according to embodiment 296, wherein p is 1.
- embodiment 298 is the compound according to embodiment 297, wherein R x is hydroxyl.
- embodiment 299 is the compound according to embodiment 295, wherein n is 1 and m is 1.
- embodiment 300 is the compound according to embodiment 299, wherein p is 0.
- embodiment 301 is the compound according to embodiment 299, wherein p is 1.
- embodiment 302 is the compound according to embodiment 301, wherein R x is oxo or hydroxyl.
- embodiment 303 is the compound according to any one of e .
- embodiment 304 is the compound according to any one of embodiments 1-303, wherein R 4 is C 1-4 alkyl, C 1-4 alkoxy, hydroxyl, halogen or C 1-4 haloalkyl.
- embodiment 305 is the compound according to embodiment 304, wherein R 4 is C 1-4 alkyl or halogen.
- embodiment 306 is the compound according to embodiment 305, wherein R 4 is fluorine.
- embodiment 307 is the compound according to embodiment 1, wherein is the compound is a compound of formula (II):
- embodiment 308 is the compound according to embodiment 1, wherein is the compound is a compound of formula (III):
- embodiment 309 is the compound according to embodiment 1, wherein is the compound is a compound of formula (IV):
- embodiment 310 is the compound according to embodiment 1, wherein is the compound is a compound of formula (V):
- embodiment 311 is the compound according to embodiment 1, wherein the compound is not: 1-(7-(8-chloronaphthalen-1-yl)-8-fluoro-2-((hexahydro-1H-pyrrolizin-7a- yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)-3-methylpiperidin-3-ol; (S)-1-(7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorohexahydro- 1H-pyrrolizin-7a-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3- methylpiperidin-3-ol; (R)-1-(7-(8-eth)-8-fluoro-2-((
- embodiment 312 is the compound according to embodiment 1, wherein the compound is not: 1-(7-(8-chloronaphthalen-1-yl)-8-fluoro-2-((hexahydro-1H-pyrrolizin-7a- yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)-3-methylpiperidin-3-ol; (S)-1-(7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorohexahydro- 1H-pyrrolizin-7a-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3- methylpiperidin-3-ol; (R)-1-(7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7
- embodiment 313 is the compound according to embodiment 1, wherein the compound is selected from one of the following compounds: 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro- 1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)azepan-3-one; (R)-1-(7-(8-Ethyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol; (R)-1-(7-(8-Cyclopropyl-3-hydroxynaphthalen
- embodiment 314 is the compound according to embodiment 1, wherein the compound is selected from one of the following compounds: 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro- 1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)azepan-3-one; (R)-1-(7-(8-Cyclopropyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3- methylpiperidin-3-ol; 3-(Difluoromethyl)-1-(7-(8-ethyl-7
- embodiment 315 is the compound according to embodiment 1, wherein the compound is selected from one of the following compounds: (R)-1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidine-3- sulfonamide; 4-(4-(Azepan-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)- yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol; 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-y
- embodiment 316 is the compound according to embodiment 1, wherein the compound is selected from one of the following compounds: 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro- 1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)azepan-3-one; (R)-1-(7-(8-Cyclopropyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3- methylpiperidin-3-ol; 3-(Difluoromethyl)-1-(7-(8-ethyl-7
- embodiment 317 is the compound according to embodiment 1, wherein the compound is selected from one of the following compounds: 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro- 1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)azepan-3-one; (R)-1-(7-(8-Cyclopropyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3- methylpiperidin-3-ol; 3-(Difluoromethyl)-1-(7-(8-ethyl-7
- embodiment 318 is the compound according to embodiment 1, wherein the compound is selected from one of the following compounds: 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro- 1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)azepan-3-one; (R)-1-(7-(8-Cyclopropyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3- methylpiperidin-3-ol; 3-(Difluoromethyl)-1-(7-(8-ethyl-7
- embodiment 319 is the compound according to embodiment 1, wherein the compound is selected from one of the following compounds: 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro- 1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-(fluoromethyl)piperidin-3- ol (Isomer 1); (R)-1-(7-(8-Ethyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol; (3R)-1-(7-(7-(8
- embodiment 320 is the compound according to embodiment 1, wherein the compound is selected from one of the following compounds: (R)-1-(7-(8-Ethyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol; (R)-1-(7-(8-Cyclopropyl-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3- methylpiperidin-3-ol; 3-(Difluoromethyl)-1-(7-(8-ethyl-3-
- embodiment 321 is the compound according to embodiment 1, wherein the compound is not example 1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 21, 22, 23, 25, 27, 28, 30, 31, 32, 33, 39, 40, 41, 44, 51, 53, 54, 55, 56, 58, 59, 65, 66, 67, 68, 69, 71, 75, 76, 81, 82, 86, 87, 89, 101, 104, 106, 108, 109, 112, 113, 116, 117, 120, 123, 129, 130, 131, 132, 134, 137, 138, 140, 144, 145, 147, 151, 153, 154, 170, 172, 173, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 197, 202, 203, 213, 221, 228, 237, 239, 240
- WO 2022/132200 International Application No. PCT/US2021/010065.
- embodiment 322 is the compound according to embodiment 1, wherein the compound is not example 1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 21, 22, 23, 25, 27, 28, 30, 31, 32, 33, 39, 40, 41, 44, 51, 53, 54, 55, 56, 58, 59, 65, 66, 67, 68, 69, 71, 75, 76, 81, 82, 86, 87, 89, 101, 104, 106, 108, 109, 112, 113, 116, 117, 120, 123, 129, 130, 131, 132, 134, 137, 138, 140, 144, 145, 147, 151, 153, 154, 170, 172, 173, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193,
- WO 2022/132200 International Application No. PCT/US2021/010065.
- a pharmaceutical composition comprising a compound disclosed herein in combination with one or more pharmaceutically acceptable excipients, such as diluents, carriers, adjuvants and the like, and, if desired, other active ingredients.
- a pharmaceutical composition comprises a therapeutically effective amount of a compound disclosed herein.
- the compound(s) disclosed herein may be administered by any suitable route in the form of a pharmaceutical composition adapted to such a route and in a dose effective for the treatment intended.
- the compounds and compositions presented herein may, for example, be administered orally, mucosally, topically, transdermally, rectally, pulmonarily, parentally, intranasally, intravascularly, intravenously, intraarterial, intraperitoneally, intrathecally, subcutaneously, sublingually, intramuscularly, intrasternally, vaginally or by infusion techniques, in dosage unit formulations containing conventional pharmaceutically acceptable excipients.
- the pharmaceutical composition may be in the form of, for example, a tablet, chewable tablet, minitablet, caplet, pill, bead, hard capsule, soft capsule, gelatin capsule, granule, powder, lozenge, patch, cream, gel, sachet, microneedle array, syrup, flavored syrup, juice, drop, injectable solution, emulsion, microemulsion, ointment, aerosol, aqueous suspension, or oily suspension.
- the pharmaceutical composition is typically made in the form of a dosage unit containing a particular amount of the active ingredient.
- embodiment 323 is a pharmaceutical composition comprising the compound according to any one of embodiments 1-322, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, and a pharmaceutically acceptable excipient.
- embodiment 324 is a compound according to any one of Embodiments 1-322, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to embodiment 323 for use as a medicament.
- the compounds described herein are to be understood to include all stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing or solvates of any of the foregoing. Accordingly, the scope of the methods and uses provided in the instant disclosure is to be understood to encompass also methods and uses employing all such forms.
- the compounds provided herein may be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. For example, animals including horses, dogs, and cats may be treated with compounds provided herein.
- the disclosure provides methods of using the compounds or pharmaceutical compositions of the present disclosure to treat disease conditions, including but not limited to conditions implicated by KRAS G12D, G12V, G12A, G12S or G12C mutation (e.g., cancer).
- the cancer types are non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma.
- KRAS G12D mutations occur with the alteration frequencies shown in the table below (TCGA data sets; 1-3 For example, the table shows that 32.4% of subjects with pancreatic cancer have a cancer wherein one or more cells express KRAS G12D mutant protein. Accordingly, the compounds provided herein, which bind to KRAS G12D (see Section entitled “Biological Evaluation” below) are useful for treatment of subjects having a cancer, including, but not limited to the cancers listed in the table below.
- embodiment 325 is a compound according to any one of embodiments 1-322 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to embodiment 323 for use in treating cancer.
- Embodiment 326 is a compound according to any one of Embodiments 1-322 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Embodiment 323 for use in treating cancer, wherein one or more cells express KRAS G12D, G12V, G12A, G12S or G12C mutant protein.
- Embodiment 327 is the compound or pharmaceutical composition for use of Embodiment 325 or 326, wherein the cancer is pancreatic cancer, colorectal cancer, non-small cell lung cancer, small bowel cancer, appendiceal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic/myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.
- the cancer is pancreatic cancer, colorectal cancer, non-small cell lung cancer, small bowel cancer, appendiceal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer,
- Embodiment 328 is a use of the compound according to any one of Embodiments 1-322 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Embodiment 323 in the preparation of a medicament for treating cancer.
- Embodiment 329 is a use of the compound according to any one of Embodiments 1-322 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Embodiment 323 in the preparation of a medicament for treating cancer, wherein one or more cells express KRAS G12D, G12V, G12A, G12S or G12C mutant protein.
- Embodiment 330 is the use according to Embodiment 328 or 329, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic/myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.
- the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendoc
- Embodiment 331 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of to any one of Embodiments 1-322 or a pharmaceutically acceptable salt thereof.
- Embodiment 332 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of to any one of Embodiments 1-322 or a pharmaceutically acceptable salt thereof, wherein one or more cells express KRAS G12D, G12V, G12A, G12S or G12C mutant protein.
- Embodiment 333 is the method according to Embodiment 331 or 332, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic/myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.
- the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine
- Embodiment 334 is the method according to Embodiment 332 or 333, wherein the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma.
- Embodiment 335 is the method according to Embodiment 334, wherein the cancer is non-small cell lung cancer.
- Embodiment 336 is the method according to Embodiment 334, wherein the cancer is colorectal cancer.
- Embodiment 337 is the method according to Embodiment 334, wherein the cancer is pancreatic cancer.
- Embodiment 338 is the method according to anyone of Embodiments 331-337, wherein the subject has a cancer that was determined to have one or more cells expressing the KRAS G12D, G12V, G12A, G12S or G12C mutant protein prior to administration of the compound or a pharmaceutically acceptable salt thereof.
- Combination Therapy The present disclosure also provides methods for combination therapies in which an agent known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
- such therapy includes but is not limited to the combination of one or more compounds of the disclosure with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide a synergistic or additive therapeutic effect.
- chemotherapeutic agents include but is not limited to the combination of one or more compounds of the disclosure with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide a synergistic or additive therapeutic effect.
- chemotherapeutic agents include but is not limited to the combination of one or more compounds of the disclosure with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide a synergistic or additive therapeutic effect.
- Embodiment 339 is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an Aurora kinase A inhibitor, AKT inhibitor, arginase inhibitor, CDK4/6 inhibitor, ErbB family inhibitor, ERK inhibitor, FAK inhibitor, FGFR inhibitor, glutaminase inhibitor, IGF- 1R inhibitor, KIF18A inhibitor, MCL-1 inhibitor, MEK inhibitor, mTOR inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PI3K inhibitor, Raf kinase inhibitor, SHP2 inhibitor, SOS1 inhibitor, Src kinase inhibitor, or one or more chemotherapeutic agent.
- the second compound is an Aurora kinase A inhibitor, AKT inhibitor, arginase inhibitor, CDK4/6 inhibitor, ErbB family inhibitor, ERK inhibitor, FAK inhibitor, FGFR inhibitor, glutaminase inhibitor, IGF- 1R inhibitor, K
- the second compound is administered as a pharmaceutically acceptable salt. In another embodiment the second compound is administered as a pharmaceutical composition comprising the second compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
- Aurora Kinase A Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an Aurora kinase A inhibitor.
- Aurora kinase A inhibitors for use in the methods provided herein include, but are not limited to, alisertib, cenisertib, danusertib, tozasertib, LY3295668 ((2R,4R)-1-[(3-chloro-2-fluorophenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3- yl)amino]pyridin-2-yl]methyl]-2-methylpiperidine-4-carboxylic acid), ENMD-2076 (6-(4- methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4- amine), TAK-901 (5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H- pyr
- AKT Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an AKT inhibitor.
- Exemplary AKT inhibitors for use in the methods provided herein include, but are not limited to, afuresertib, capivasertib, ipatasertib, uprosertib, BAY1125976 (2-[4-(1- aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide), ARQ 092 (3- [3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine), MK2206 (8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,
- Arginase Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an arginase inhibitor.
- Exemplary arginase inhibitors for use in the methods provided herein include, but are not limited to, numidargistat and CB 280.
- CDK4/6 Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a CDK4/6 inhibitor.
- CDK 4/6 refers to cyclin dependent kinases (“CDK”) 4 and 6, which are members of the mammalian serine/threonine protein kinases.
- CDK 4/6 inhibitor refers to a compound that is capable of negatively modulating or inhibiting all or a portion of the enzymatic activity of CDK 4 and/or 6.
- CDK 4/6 inhibitors for use in the methods provided herein include, but are not limited to, abemaciclib, palbociclib, ribociclib, trilaciclib, and PF-06873600 ((pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2- methylcyclopentyl]-2-[[1-(methylsulfony1)-4-piperidinyl]amino]).
- the CDK4/6 inhibitor is palbociclib.
- ErbB Family Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an ErbB family inhibitor.
- the term “ErbB family” as used herein refers to a member of a mammalian transmembrane protein tyrosine kinase family including: ErbB1 (EGFR HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4).
- ErbB family inhibitor refers to an agent, e.g., a compound or antibody, that is capable of negatively modulating or inhibiting all or a portion of the activity of at least one member of the ErbB family.
- the modulation or inhibition of one or more ErbB tyrosine kinase may occur through modulating or inhibiting kinase enzymatic activity of one or more ErbB family member or by blocking homodimerization or heterodimerization of ErbB family members.
- the ErbB family inhibitor is an EGFR inhibitor, e.g., an anti- EGFR antibody.
- Exemplary anti-EGFR antibodies for use in the methods provided herein include, but are not limited to, zalutumumab, nimotuzumab, matuzumab, necitumumab, panitumumab, and cetuximab.
- the anti-EGFR antibody is cetuximab.
- the anti-EGFR antibody is panitumumab.
- the ErbB family inhibitor is a HER2 inhibitor, e.g., an anti- HER2 antibody.
- Exemplary anti-HER-2 antibodies for use in the methods provided herein include, but are not limited to, pertuzumab, trastuzumab, and trastuzumab emtansine.
- the ErbB family inhibitor is a HER3 inhibitor, e.g., an anti-HER3 antibody, such as HMBD-001 (Hummingbird Bioscience).
- the ErbB family inhibitor is a combination of an anti-EGFR antibody and anti-HER2 antibody.
- the ErbB family inhibitor is an irreversible inhibitor.
- Exemplary irreversible ErbB family inhibitors for use in the methods provided herein include, but are not limited to, afatinib, dacomitinib, canertinib, poziotinib, AV 412 ((N-[4-[(3-chloro-4- fluorophenyl)amino]-7-[3-methyl-3-(4-methyl-1-piperazinyl)-1-butyn-1-yl]-6-quinazolinyl]- 2-propenamide)), PF 6274484 ((N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6- quinazolinyl]-2-propenamide), and HKI 357 ((E)-N-[4-[3-chloro-4-[(3- fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(di
- the irreversible ErbB family inhibitor is afatinib. In one embodiment, the irreversible ErbB family inhibitor is dacomitinib. In one embodiment, the ErbB family inhibitor is a reversible inhibitor.
- Exemplary reversible ErbB family inhibitors for use in the methods provided herein include, but are not limited to erlotinib, gefitinib, sapitinib, varlitinib, tarloxotinib, TAK-285 (N-(2-(4-((3-chloro- 4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3- hydroxy-3-methylbutanamide), AEE788 ((S)-6-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-N- (1-phenylethyl)-7H-pyrrolo[2,
- the reversible ErbB family inhibitor is sapitinib. In one embodiment, the reversible ErbB family inhibitor is tarloxotinib.
- ERK Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an ERK inhibitor.
- Exemplary ERK inhibitors for use in the methods provided herein include, but are not limited to, ulixertinib, ravoxertinib, CC-90003 (N-[2-[[2-[(2-methoxy-5-methylpyridin-4- yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-5-methylphenyl]prop-2-enamide), LY3214996 (6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2- morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one), KO-947 (1,5,6,8-tetrahydro-6- (phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one), ASTX029, LTT462, and JSI-1187.
- FAK Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a FAK inhibitor.
- Exemplary FAK inhibitors for use in the methods provided herein include, but are not limited to, GSK2256098 (2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3- yl)amino]pyridin-4-yl]amino]-N-methoxybenzamide), PF-00562271 (N-methyl-N-[3-[[[2- [(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4- yl]amino]methyl]pyridin-2-yl]methanesulfonamide), VS-4718 (2-[[2-(2-methoxy-4- morpholin-4-
- FGFR Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an FGFR inhibitor.
- Exemplary FGFR inhibitors for use in the methods provided herein include, but are not limited to, futibatinib, pemigatinib, ASP5878 (2-[4-[[5-[(2,6-difluoro-3,5- dimethoxyphenyl)methoxy]pyrimidin-2-yl]amino]pyrazol-1-yl]ethanol), AZD4547 (N-[5-[2- (3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1- yl]benzamide), debio 1347 ([5-amino-1-(2-methyl-3H-benzimidazol-5-y
- Glutaminase Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a glutaminase inhibitor.
- Exemplary glutaminase inhibitors for use in the methods provided herein include, but are not limited to, telaglenastat, IPN60090, and OP 330.
- IGF-1R Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an IGF-1R inhibitor.
- IGF-1R inhibitors for use in the methods provided herein include, but are not limited to, cixutumumab, dalotuzumab, linsitinib, ganitumab, robatumumab, BMS- 754807 ((2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]- N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide), KW-2450 (N-[5-[[4-(2- hydroxyacetyl)piperazin-1-yl]methyl]-2-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-3- methylthiophene-2-carboxamide), PL225B, AVE1642, and BIIB022.
- KIF18A Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a KIF18A inhibitor.
- Exemplary KIF18A inhibitors for use in the methods provided herein include, but are not limited to, the inhibitors disclosed in US 2020/0239441, WO 2020/132649, WO 2020/132651, and WO 2020/132653, each of which is herewith incorporated by reference in its entirety.
- MCL-1 Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an MCL-1 inhibitor.
- MEK inhibitors for use in the methods provided herein include, but are not limited to, murizatoclax, tapotoclax, AZD 5991 ((3aR)-5-chloro-2,11,12,24,27,29- hexahydro-2,3,24,33-tetramethyl-22H-9,4,8-(metheniminomethyno)-14,20:26,23-dimetheno- 10H,20H-pyrazolo[4,3-l][2,15,22,18,19]benzoxadithiadiazacyclohexacosine-32-carboxylic acid), MIK 665 (( ⁇ R)- ⁇ -[[(5S)-5-[3-Chloro-2-methyl-4-[2-(4-methyl-1- piperazinyl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy]-2-[[2-(2-(
- the MCL-1 inhibitor is murizatoclax. In another embodiment, the MCL-1 inhibitor is tapotoclax.
- MEK Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is MEK inhibitor.
- MEK inhibitors for use in the methods provided herein include, but are not limited to, trametinib, cobimetinib, selumetinib, pimasertib, refametinib, PD-325901 (N- [(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide), AZD8330 (2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3- carboxamide), GDC-0623 (5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5- a]pyridine-6-carboxamide), RO4987655 (3,4-difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-(2-
- the MEK inhibitor is trametinib.
- mTOR Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an mTOR inhibitor.
- Exemplary mTOR inhibitors for use in the methods provided herein include, but are not limited to, everolimus, rapamycin, zotarolimus (ABT-578), ridaforolimus (deforolimus, MK-8669), sapanisertib, buparlisib, pictilisib, vistusertib, dactolisib, Torin-1 (1-(4-(4- propionylpiperazin-1-yl)-3-(trifluoromethyl)cyclohexyl)-9-(quinolin-3- yl)benzo[h][1,6]naphthyridin-2(1H)-one), GDC-0349 ((S)-1-ethyl-3-(4-(4-(3- methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl)phenyl)ure
- the mTOR inhibitor is everolimus.
- PD-1 Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a PD-1 inhibitor.
- Exemplary PD-1 inhibitors for use in the methods provided herein include, but are not limited to, pembrolizumab, nivolumab, cemiplimab, spartalizumab (PDR001), camrelizumab (SHR1210), sintilimab (IBI308), tislelizumab (BGB-A317), toripalimab (JS 001), dostarlimab (TSR-042, WBP-285), INCMGA00012 (MGA012), AMP-224, AMP-514, and the anti-PD-1 antibody as described in US 10,640,504 B2 (the “Anti-PD-1 Antibody A,” column 66, line 56 to column 67, line 24 and column 67, lines 54-57), which is incorporated herein by reference.
- the PD-1 inhibitor is pembrolizumab. In another embodiment the PD-1 inhibitor is the Anti-PD-1 Antibody A.
- PD-L1 Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a PD-L1 inhibitor.
- Exemplary PD-L1 inhibitors for use in the methods provided herein include, but are not limited to, atezolizumab, avelumab, durvalumab, ZKAB001, TG-1501, SHR-1316, MSB2311, MDX-1105, KN035, IMC-001, HLX20, FAZ053, CS1001, CK-301, CBT-502, BGB-A333, BCD-135, and A167.
- the PD-L1 inhibitor is atezolizumab.
- PI3K Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a PI3K inhibitor.
- PI3K inhibitors for use in the methods provided herein include, but are not limited to, idelalisib, copanlisib, duvelisib, alpelisib, taselisib, perifosine, buparlisib, umbralisib, pictilisib, dactolisib, voxtalisib, sonolisib, tenalisib, serabelisib, acalisib, CUDC- 907 (N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6- yl]methyl-methylamino]pyrimidine
- Raf Kinase Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a Raf kinase inhibitor.
- RAF kinase refers to a member of a mammalian serine/threonine kinases composed of three isoforms (C-Raf, B-Raf and A-Raf) and includes homodimers of each isoform as well as heterodimers between isoforms, e.g., C-Raf/B-Raf heterodimers.
- Raf kinase inhibitor refers to a compound that is capable of negatively modulating or inhibiting all or a portion of the enzymatic activity of one or more member of the Raf family kinases, or is capable of disrupting Raf homodimer or heterodimer formation to inhibit activity.
- the Raf kinase inhibitor includes, but is not limited to, encorafenib, sorafenib, lifirafenib, vemurafenib, dabrafenib, PLX-8394 (N-(3-(5-(2- cyclopropylpyrimidin-5-yl)-3a,7a-dihydro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4- difluorophenyl)-3-fluoropyrrolidine-1-sulfonamide), Raf-709 (N-(2-methyl-5,-morpholino- 6’-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide), LXH254 (N-(3-(2-(2-hydroxyethoxy)-6- morpholinopyridin-4-yl)
- the Raf kinase inhibitor is encorafenib. In one embodiment, the Raf kinase inhibitor is sorafenib. In one embodiment, the Raf kinase inhibitor is lifirafenib.
- SHP2 Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a SHP2 inhibitor.
- Exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to, SHP-099 (6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin- 2-amine dihydrochloride), RMC-4550 ([3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol), TNO155, (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa- 8-azaspiro[4.5]decan-4-amine), and RMC-4630 (Revolution Medicine).
- the SHP inhibitor for use in the methods provided herein is RMC-4630 (Revolution Medicine).
- exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to, 3-[(1R,3R)-1-amino-3-methoxy-8-azaspiro[4.5]dec-8- yl]-6-(2,3-dichlorophenyl)-5-methyl-2-pyrazinemethanol (CAS 2172651-08-8), 3-[(3S,4S)-4- amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-methyl-2- pyrazinemethanol (CAS 2172652-13-8), 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]dec-8-yl]-6-[[3-chloro-2-(3-hydroxy-1-azet)
- exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to, 1-[5-(2,3-dichlorophenyl)-6-methylimidazo[1,5- a]pyrazin-8-yl]-4-methyl-4-piperidinamine (CAS 2240981-75-1), (1R)-8-[5-(2,3- dichlorophenyl)-6-methylimidazo[1,5-a]pyrazin-8-yl]-8-azaspiro[4.5]decan-1-amine (CAS 2240981-78-4), (3S,4S)-8-[7-(2,3-dichlorophenyl)-6-methylpyrazolo[1,5-a]pyrazin-4-yl]-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (CAS 2240982-45-8), (3S,4S)-8-[7-[(2-amino-3- chloro-4-pyridinyl)thio]pyra
- the SHP inhibitor for use in the methods provided herein is (1R)- 8-[5-(2,3-dichlorophenyl)-6-methylimidazo[1,5-a]pyrazin-8-yl]-8-azaspiro[4.5]decan-1- amine (CAS 2240981-78-4).
- exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to 3-[(1R)-1-amino-8-azaspiro[4.5]dec-8-yl]-6-(2,3- dichlorophenyl)-5-hydroxy-2-pyridinemethanol (CAS 2238840-54-3), 3-[(1R)-1-amino-8- azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-hydroxy-2-pyridinemethanol (CAS 2238840-56-5), 5-[(1R)-1-amino-8-azaspiro[4.5]dec-8-yl]-2-(2,3-dichlorophenyl)-3-pyridinol (CAS 2238840-58-7), 3-[(1R)-1-amino-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5- methyl-2-pyridinem
- the SHP inhibitor for use in the methods provided herein is 3- [(1R)-1-amino-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-hydroxy-2- pyridinemethanol (CAS 2238840-56-5).
- the SHP2 inhibitor for use in the methods provided herein is an inhibitor disclosed in US 10,590,090 B2, US 2020/017517 A1, US 2020/017511 A1, or WO 2019/075265 A1, each of which is herewith incorporated by reference in its entirety.
- SOS1 Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an SOS1 inhibitor.
- exemplary SOS1 inhibitors for use in the methods provided herein include, but are not limited to, BI 3406 (N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2- methyl-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine), and BI 1701963.
- Src Kinase Inhibitors Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a Src kinase inhibitor.
- the term “Src kinase” as used herein refers to a member of a mammalian nonreceptor tyrosine kinase family including: Src, Yes, Fyn, and Fgr (SrcA subfamily); Lck, Hck, Blk, and Lyn (SrcB subfamily), and Frk subfamily.
- the Src kinase inhibitor is dasatinib. In one embodiment, the Src kinase inhibitor is saracatinib. In one embodiment, the Src kinase inhibitor is ponatinib. In one embodiment, the Src kinase inhibitor is vandetanib. In one embodiment, the Src kinase inhibitor is KX-01.
- Chemotherapeutic Agents Provided herein is the method according to anyone of Embodiments 331-338, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is one or more chemotherapeutic agent.
- chemotherapeutic agents for use in the methods provided herein include, but are not limited to, leucovorin calcium (calcium folinate), 5-fluorouracil, irinotecan, oxaliplatin, cisplatin, carboplatin, pemetrexed, docetaxel, paclitaxel, gemcitabine, vinorelbine, chlorambucil, cyclophosphamide, and methotrexate.
- Stereoisomers may contain, for example, double bonds, one or more asymmetric carbon atoms, and bonds with a hindered rotation, and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers (E/Z)), enantiomers, diastereomers, and atropoisomers.
- double-bond isomers i.e., geometric isomers (E/Z)
- enantiomers e.e., diastereomers, and atropoisomers.
- the scope of the instant disclosure is to be understood to encompass all possible stereoisomers of the illustrated compounds, including the stereoisomerically pure form (for example, geometrically pure, enantiomerically pure, diastereomerically pure, and atropoisomerically pure) and stereoisomeric mixtures (for example, mixtures of geometric isomers, enantiomers, diastereomers, and atropoisomers, or mixture of any of the foregoing) of any chemical structures disclosed herein (in whole or in part), unless the stereochemistry is specifically identified.
- stereoisomerically pure form for example, geometrically pure, enantiomerically pure, diastereomerically pure, and atropoisomerically pure
- stereoisomeric mixtures for example, mixtures of geometric isomers, enantiomers, diastereomers, and atropoisomers, or mixture of any of the foregoing
- stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it. If the stereochemistry of a structure or a portion of a structure is indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing only the stereoisomer indicated.
- a bond drawn with a wavy line indicates that both stereoisomers are encompassed. This is not to be confused with a wavy line drawn perpendicular to a bond which indicates the point of attachment of a group to the rest of the molecule.
- stereoisomer or “stereoisomerically pure” compound as used herein refers to one stereoisomer (for example, geometric isomer, enantiomer, diastereomer and atropoisomer) of a compound that is substantially free of other stereoisomers of that compound.
- a stereoisomerically pure compound having one chiral center will be substantially free of the mirror image enantiomer of the compound and a stereoisomerically pure compound having two chiral centers will be substantially free of other enantiomers or diastereomers of the compound.
- a typical stereoisomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and equal or less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and equal or less than about 10% by weight of the other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and equal or less than about 5% by weight of the other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and equal or less than about 3% by weight of the other stereoisomers of the compound.
- This disclosure also encompasses the pharmaceutical compositions comprising stereoisomerically pure forms and the use of stereoisomerically pure forms of any compounds disclosed herein.
- this disclosure also encompasses pharmaceutical compositions comprising mixtures of stereoisomers of any compounds disclosed herein and the use of said pharmaceutical compositions or mixtures of stereoisomers. These stereoisomers or mixtures thereof may be synthesized in accordance with methods well known in the art and methods disclosed herein. Mixtures of stereoisomers may be resolved using standard techniques, such as chiral columns or chiral resolving agents. Further, this disclosure encompasses pharmaceutical compositions comprising mixtures of any of the compounds disclosed herein and one or more other active agents disclosed herein.
- isotopes suitable for inclusion in the compounds disclosed herein include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 CI, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
- isotopically-labelled compounds of Formula I for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
- radioactive isotopes tritium ( 3 H) and carbon-14 ( 14 C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- substitution with isotopes such as deuterium ( 2 H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be advantageous in some circumstances.
- substitution with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N can be useful in Positron Emission Topography (PET) studies, for example, for examining target occupancy.
- PET Positron Emission Topography
- Isotopically- labelled compounds of the compounds disclosed herein can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying General Synthetic Schemes and Examples using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed.
- Solvates As discussed above, the compounds disclosed herein and the stereoisomers, tautomers, and isotopically-labelled forms thereof or a pharmaceutically acceptable salt of any of the foregoing may exist in solvated or unsolvated forms.
- solvate refers to a molecular complex comprising a compound or a pharmaceutically acceptable salt thereof as described herein and a stoichiometric or non-stoichiometric amount of one or more pharmaceutically acceptable solvent molecules. If the solvent is water, the solvate is referred to as a “hydrate.” Accordingly, the scope of the instant disclosure is to be understood to encompass all solvents of the compounds disclosed herein and the stereoisomers, tautomers and isotopically-labelled forms thereof or a pharmaceutically acceptable salt of any of the foregoing. Miscellaneous Definitions This section will define additional terms used to describe the scope of the compounds, compositions and uses disclosed herein.
- aryl refers to an aromatic hydrocarbon group having 6-20 carbon atoms in the ring portion. Typically, aryl is monocyclic, bicyclic or tricyclic aryl having 6-20 carbon atoms. Furthermore, the term “aryl” as used herein, refers to an aromatic substituent which can be a single aromatic ring, or multiple aromatic rings that are fused together.
- Non-limiting examples include phenyl, naphthyl or tetrahydronaphthyl, each of which may optionally be substituted with 1-4 substituents, such as alkyl, trifluoromethyl, cycloalkyl, halogen, hydroxy, alkoxy, acyl, alkyl-C(O)-O-, aryl-O-, heteroaryl-O-, amino, thiol, alkyl-S-, aryl-S--- nitro, cyano, carboxy, alkyl-O-C(O)--, carbamoyl, alkyl-S(O)-, sulfonyl, sulfonamido, phenyl, and heterocycloalkyl.
- substituents such as alkyl, trifluoromethyl, cycloalkyl, halogen, hydroxy, alkoxy, acyl, alkyl-C(O)-O-, aryl-O-,
- C 1-4 alkyl and “C 1-6 alkyl” as used herein refer to a straight or branched chain hydrocarbon containing from 1 to 4, and 1 to 6 carbon atoms, respectively.
- Representative examples of C 1-4 alkyl or C 1-6 alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl and hexyl.
- C 1-4 alkylene and “C 1-6 alkylene” refer to a straight or branched divalent alkyl group as defined herein containing 1 to 4, and 1 to 6 carbon atoms, respectively.
- alkylene examples include, but are not limited to, methylene, ethylene, n- propylene, iso-propylene, n-butylene, sec-butylene, iso-butylene, tert-butylene, n-pentylene, isopentylene, neopentylene, n-hexylene and the like.
- C 2-4 alkenyl refers to a saturated hydrocarbon containing 2 to 4 carbon atoms having at least one carbon-carbon double bond. Alkenyl groups include both straight and branched moieties.
- C 2-4 alkenyl include, but are not limited to, 1-propenyl, 2-propenyl, 2-methyl-2-propenyl, and butenyl.
- C 2-4 alkynyl refers to a saturated hydrocarbon containing 2 to 4 carbon atoms having at least one carbon-carbon triple bond. The term includes both straight and branched moieties.
- Representative examples of C 3-6 alkynyl include, but are not limited to, ethynyl, 1 -propynyl, 2-propynyl, 2-butynyl and 3-butynyl.
- C 1-4 alkoxy or “C 1-6 alkoxy” as used herein refers to –OR # , wherein R # represents a C 1-4 alkyl group or C 1-6 alkyl group, respectively, as defined herein.
- Representative examples of C 1-4 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, iso-propoxy, and butoxy.
- Representative examples of C 1-6 alkoxy include, but are not limited to, ethoxy, propoxy, iso-propoxy, and butoxy.
- C 3-8 cycloalkyl refers to a saturated carbocyclic molecule wherein the cyclic framework has 3 to 8 carbons.
- C 3-8 cycloalkyl include, but are not limited to, cyclopropyl and cyclobutyl.
- deutero as used herein as a prefix to another term for a chemical group refers to a modification of the chemical group, wherein one or more hydrogen atoms are substituted with deuterium (“D” or “ 2 H”).
- D deuterium
- C 1-4 deuteroalkyl refers to a C 1-4 alkyl as defined herein, wherein one or more hydrogen atoms are substituted with D.
- C 1-4 deuteroalkyl include, but are not limited to, -CH 2 D, -CHD 2 , - CD 3 , -CH 2 CD 3 , -CDHCD 3 , -CD 2 CD 3 , -CH(CD 3 ) 2 , -CD(CHD 2 ) 2 , and -CH(CH 2 D)(CD 3 ).
- halogen refers to –F, -CI, -Br, or -I.
- halo as used herein as a prefix to another term for a chemical group refers to a modification of the chemical group, wherein one or more hydrogen atoms are substituted with a halogen as defined herein.
- C 1-4 haloalkyl refers to a C 1-4 alkyl as defined herein, wherein one or more hydrogen atoms are substituted with a halogen.
- Representative examples of C 1- 4 haloalkyl include, but are not limited to, -CH 2 F, -CHF 2 , -CF 3 , -CHFCl, -CH 2 CF 3 , -CFHCF 3 , -CF 2 CF 3 , -CH(CF 3 ) 2 , -CF(CHF 2 ) 2 , and -CH(CH 2 F)(CF 3 ).
- heteroaryl refers to a 5-20 membered monocyclic- or bicyclic- or tricyclic-aromatic ring system, having 1 to 8 heteroatoms selected from N, O and S.
- the heteroaryl is a 5-10 membered ring system (e.g., 5-7 membered monocycle, an 8-10 membered bicycle or a 11-14 membered tricycle) or a 5-7 membered ring system.
- Exemplary monocyclic heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, and 2-, 4-, and 5-pyrimidinyl.
- Exemplary bicyclic heteroaryl groups include 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 1-, 2-, 4-, 5-, 6-, 7-, or 8-benzimidazolyl and 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8- indolyl.
- heteroaryl also refers to a group in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocycloalkyl rings.
- heterocycle refers to a saturated or unsaturated non-aromatic ring or ring system, e.g., which is a 4-, 5-, 6-, or 7- membered monocyclic, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic or 10-, 11-, 12-, 13-, 14- or 15-membered tricyclic ring system and contains at least one heteroatom selected from O, S and N, where the N and S can also optionally be oxidized to various oxidation states.
- the heterocyclic group can be attached at a heteroatom or a carbon atom.
- the heterocycloalkyl can include fused or bridged rings as well as spirocyclic rings.
- heterocycles include tetrahydrofuran, dihydrofuran, 1, 4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3-dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane, thiomorpholine, azetidine, thiazolidine, morpholine, and the like.
- pharmaceutically acceptable refers to generally recognized for use in subjects, particularly in humans.
- pharmaceutically acceptable salt refers to a salt of a compound that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
- Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, for example, an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-
- excipient refers to a broad range of ingredients that may be combined with a compound or salt disclosed herein to prepare a pharmaceutical composition or formulation.
- excipients include, but are not limited to, diluents, colorants, vehicles, anti-adherants, glidants, disintegrants, flavoring agents, coatings, binders, sweeteners, lubricants, sorbents, preservatives, and the like.
- subject refers to humans and mammals, including, but not limited to, primates, cows, sheep, goats, horses, dogs, cats, rabbits, rats, and mice. In one embodiment the subject is a human.
- therapeutically effective amount refers to that amount of a compound disclosed herein that will elicit the biological or medical response of a tissue, a system, or subject that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- GENERAL SYNTHETIC PROCEDURES The compounds provided herein can be synthesized according to the procedures described in this and the following sections.
- the compounds disclosed herein may also be synthesized by alternate routes utilizing alternative synthetic strategies, as appreciated by persons of ordinary skill in the art. It should be appreciated that the general synthetic procedures and specific examples provided herein are illustrative only and should not be construed as limiting the scope of the present disclosure in any manner.
- the compounds of Formula I can be synthesized according to the following schemes. Any variables used in the following schemes are the variables as defined for Formula I, unless otherwise noted. All starting materials are either commercially available, for example, from Merck Sigma-Aldrich Inc., Fluorochem Ltd, and Enamine Ltd. or known in the art and may be synthesized by employing known procedures using ordinary skill.
- step A compound (I-1) is treated with an aliphatic alcohol, such as benzyl alcohol, and a base, such as Hunig’s base, or metal alkoxide, such as potassium tert-butoxide, in a solvent such as 1,4-dioxane to give compound (I-2).
- an aliphatic alcohol such as benzyl alcohol
- a base such as Hunig’s base
- metal alkoxide such as potassium tert-butoxide
- step B compound (I-2) undergoes S N Ar reaction with a nucleophile having the formula R 1 -L-H in a solvent such as acetonitrile, in the presence of a base such as Hunig’s base, to give compound (I-3).
- step C compound (I-3) is coupled with an organometallic reagent or a boronic acid (ester) to provide compound (I-4).
- This coupling reaction proceeds in a solvent or mixture of solvents such as 1,4-dioxane and water, and a catalyst such as cataCXium A Pd G3, with or without a base such as potassium phosphate.
- step D compound (I-4) is treated with a suitable set of reagents, such as Pd/C with H 2 to remove the alkyl group R, giving compound (I-5).
- Step E compound (I-5) is treated with an optionally substituted cyclic amine in the presence of coupling reagent such as HATU, and a base such as Hunig’s base, in a solvent such as DMA to give compounds of Formula (I).
- the species R 3 will contain protecting group(s), which can be removed in step D or after step E in the synthetic sequence.
- compound (I-1) is treated with sodium thiomethoxide in a solvent such as tetrahydrofuran to give compound (I-6).
- step B compound (I-6) undergoes SNAr reaction with a nucleophile having the formula R 1 -L-H in a solvent such as acetonitrile in the presence of a base such as Hunig’s base to give compound (I-7).
- step C compound (I-7) is coupled with an organometallic reagent or a boronic acid (ester) to provide compound (I-8).
- This coupling reaction proceeds in a solvent or mixture of solvents such as 1,4-dioxane and water, and a catalyst such as cataCXium A Pd G3, with or without a base such as potassium phosphate.
- step D compound (I-8) is coupled with an optionally substituted cyclic amine in the presence of a palladium catalyst, such as Pd(PPh 3 ) 4 , a copper catalyst, such as CuTC, in a solvent such as 1,4-dioxane, to give compounds of formula (I).
- a palladium catalyst such as Pd(PPh 3 ) 4
- a copper catalyst such as CuTC
- a solvent such as 1,4-dioxane
- Scheme III Compounds of Formula (I) can also be prepared according to Scheme III.
- step A compound (I-8) is treated with sulfuryl chloride in a solvent such as dichloromethane to give compound (I-9).
- step B compound (I-9) undergoes S N Ar reaction with an optionally substituted cyclic amine in a solvent such as acetonitrile in the presence of a base such as Hunig’s base to give compounds of formula (I).
- the species R 3 will contain protecting group(s), which can be removed after step B in the synthetic sequence.
- step A compound (1) undergoes SNAr reaction with an optionally substituted cyclic amine in a solvent such as dichloromethane and in the presence of a base such as Hunig’s base to give compound (I-10).
- step B compound (I-10) undergoes S N Ar reaction with a nucleophile having the formula R 1 -L-H in a solvent such as acetonitrile, in the presence of a base such as Hunig’s base to give compound (I-11).
- step C compound (I-11) is coupled with an organometallic reagent or a boronic acid (ester) to provide compounds of formula (I).
- Preparative HPLC Method where indicated, the compounds described herein were purified via reverse phase HPLC using Waters FractionLynx or Gilson semi-preparative HPLC-MS system utilizing one of the following two HPLC columns: (a) Phenomenex Gemini column (5 micron, C18, 150 x 30 mm) or (b) Waters X-select CSH column (5 micron, C18, 100 x 30 mm). A typical run through the instrument included: eluting at 45 mL/min with a linear gradient of 10% (v/v) to 100% MeCN (0.1% v/v formic acid) in water (0.1% formic acid) over 10 minutes; conditions can be varied to achieve optimal separations.
- a microwave vial was charged with methyl 2-(2-bromo-3,4-difluorophenyl)acetate (1.62 g, 6.11 mmol), trifluorotoluene (15 mL), tributyl(1-ethoxyvinyl)stannane (4.41 g, 12.22 mmol), and trans- dichlorobis(triphenyl-phosphine)palladium (II) (0.86 g, 1.22 mmol).
- the vial was purged with nitrogen for 2 min, sealed, and placed in a microwave reactor for 12 h at 150 o C. Upon completion, the mixture was filtered through a celite / silica plug and concentrated.
- Step 3 7,8-Difluoronaphthalene-1,3-diol.
- methyl 2-(2-acetyl-3,4-difluorophenyl)acetate (1.21 g, 5.30 mmol)
- KOtBu (1.79 g, 15.91 mmol
- THF 40 mL
- Step 5 7,8-Difluoro-3-((triisopropylsilyl)oxy)naphthalen-1-yl trifluoromethanesulfonate.
- 78-difluoro-3- ((triisopropylsilyl)oxy)naphthalen-1-ol (0.88 g, 2.50 mmol)
- DIPEA 1.31 mL, 7.51 mmol
- DCM 25 mL
- Tf 2 O (1 M in DCM, 2.76 mL, 2.76 mmol
- Step 6 ((5,6-Difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)naphthalen-2-yl)oxy)triisopropylsilane.
- a 100-mL round-bottomed flask was charged - 128 - with 7,8-difluoro-3-((triisopropylsilyl)oxy)naphthalen-1-yl trifluoromethanesulfonate (1.21 g, 2.50 mmol), bis(pinacalato)diboron (1.27 g, 4.99 mmol), potassium acetate (0.86 g, 8.74 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium dichloride (0.37 g, 0.499 mmol) and toluene (25 mL).
- Step 1 7-Fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-ol.
- a pressure relief vial was charged with potassium acetate (1.21 g, 12.3 mmol, Sigma Aldrich), 7-fluoro-1- naphthol (1.00 g, 6.17 mmol, Enamine), dichloro(p-cymene)ruthenium(II)dimer (0.38 g, 0.62 mmol, Alfa Aesar) and then purged with nitrogen for 5 min.
- Step 3 8-Ethyl-7-fluoronaphthalen-1-ol.
- a scintillation vial was charged with 7- fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl pivalate (1.13 g, 2.65 mmol) and dissolved in DMF (12 mL).
- Cesium fluoride (4.02 g, 26.5 mmol, Sigma-Aldrich Corporation) was added and the mixture stirred at rt for 30 minutes. Water (100 mL) was added and the aqueous phase extracted with EtOAc (2 ⁇ 20 mL).
- TEA 0.28 g, 0.39 mL, 2.76 mmol, Sigma-Aldrich Corporation
- a 1 M Tf 2 O solution (2.02 mL, 2.02 mmol, Sigma-Aldrich Corporation).
- the mixture was stirred at rt for 20 minutes and poured into ice water (20 mL).
- the aqueous phase was extracted with DCM (2 x 10 mL), the combined organic layers were dried over Na 2 SO 4 and volatiles were removed in vacuo.
- the crude mixture was purified by column chromatography on silica gel, eluting using a gradient of 0-5% EtOAc in heptane to yield 8- ethyl-7-fluoronaphthalen-1-yl trifluoromethanesulfonate (0.47 g, 1.47 mmol, 80 % yield) as colorless oil.
- Potassium acetate (0.43 g, 4.38 mmol, Sigma-Aldrich Corporation) was placed in a pressure relief vial and dried under vacuum. Then, 8-ethyl-7-fluoronaphthalen-1- yl trifluoromethanesulfonate (0.47 g, 1.46 mmol), bis(pinacalato)diboron (0.74 g, 2.92 mmol, Combi-Blocks Inc.) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.11 g, 0.15 mmol, Sigma-Aldrich Corporation) were added and the mixture stirred at 90 °C for 3 h and then at rt for 12 h.
- Step 1 4-(Benzyloxy)-2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidine.
- a 250-mL round-bottom flask charged with activated 3 ⁇ molecular sieves was added 1,4-dioxane (48 mL), DIPEA (9.22 g, 12.5 mL, 71.3 mmol), benzyl alcohol (3.86 g, 3.7 mL, 35.7 mmol) and 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine (6.00 g, 23.8 mmol). The mixture was stirred at 85 °C for 2 h.
- Step 2 4-(Benzyloxy)-7-chloro-8-fluoro-2-(((2S,7aR)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidine.
- Step 3 4-(Benzyloxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)- 8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidine.
- reaction mixture was stirred at 70 °C for 2 h.
- the reaction mixture was purified by column chromatography on silica gel, eluting with 0-50% 3:1 EtOAc/EtOH blend in heptane with 2% triethylamine additive to yield 4-(benzyloxy)-7-(8-ethyl-7-fluoro-3- (methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidine (2.42 g, 3.75 mmol, 65 % yield).
- Step 4 7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2- (((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-4-ol.
- Step 3 4-(tert-Butoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)- 8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidine.
- Step 4 7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-ol.
- Step 2 7-Chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl)methoxy)-4-(methylthio)pyrido[4,3-d]pyrimidine.
- Step 3 7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2- (((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4- (methylthio)pyrido[4,3-d]pyrimidine.
- reaction was stirred at 85 °C for 1.5 h.
- the reaction mixture was concentrated under reduced pressure and purified by column chromatography twice, eluting with first a gradient of 0-50% (20% MeOH in DCM) in DCM, then 0-50% 3:1 EtOAc/EtOH in heptane with 2% triethylamine additive to afford 7-(8-ethyl- 7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy)-4-(methylthio)pyrido[4,3-d]pyrimidine (1.50 g, 2.57 mmol, 42 % yield) as yellow solid.
- ammonium hydroxide (4.20 g, 4.6 mL, 0.12 mol, Fisher Scientific) was added and the reaction was stirred at the same temperature overnight. The organic solvent was removed under reduced pressure. The remaining solution was then diluted with EtOAc (10 mL) and the organic layer was washed with 10% aq. citric acid (10 mL), saturated aqueous sodium bicarbonate (10 mL), and brine (10 mL).
- Benzyl 3-hydroxy-3-methylazepane-1-carboxylate (0.24 g) was purified via SFC using a Chiralpak IG, 21 ⁇ 250 mm 5 ⁇ m, column with a mobile phase of 20% methanol with 0.2% triethylamine using a flowrate of 80 mL/min to generate 89 mg of peak 1 with an ee of >99% and 91 mg of peak 2 with an ee of >99%.
- Step 3 3-Methylazepan-3-ol hydrochloride. Benzyl 3-hydroxy-3-methylazepane- 1-carboxylate (89 mg, 0.34 mmol, Peak 1) was dissolved in ethanol (1.7 mL).
- Step 2 tert-Butyl 6-cyano-3-azabicyclo[3.2.2]nonane-3-carboxylate.
- a stirring solution of tert-butyl 6-carbamoyl-3-azabicyclo[3.2.2]nonane-3-carboxylate (0.13 g, 0.47 mmol) in pyridine (1.2 mL) was added 1H-imidazole (63 mg, 0.93 mmol, Sigma Aldrich).
- the resultant mixture was cooled to 0 °C, and phosphorous oxychloride (0.29 g, 0.17 mL, 1.86 mmol, Sigma-Aldrich Corporation) was added slowly dropwise and the mixture kept at the same temperature.
- Step 3 8-Oxa-3-azabicyclo[3.2.1]octane-6-carbonitrile hydrochloride.
- tert-Butyl 6-cyano-3-azabicyclo[3.2.2]nonane-3-carboxylate (94 mg, 0.38 mmol) was then dissolved in MeCN (3.5 mL) and HCl in 1,4-dioxane (4 M, 0.47 mL, 1.86 mmol, Sigma-Aldrich Corporation) was added.
- Step 1 (E)-5-Chloro-6-fluoro-3,4-dihydronaphthalen-1(2H)-one oxime.
- 5-chloro-6-fluoro-3,4-dihydronaphthalen-1(2H)-one (0.40 kg, 2.01 mol) in EtOH (2.4 L) and H 2 O (0.8 L) was added NaOAc (0.25 kg, 3.02 mol) and NH 2 OH•HCl (0.21 kg, 3.02 mol).
- the reaction was stirred at 25 °C for 12 h.
- Four reactions were carried out in parallel, and were combined for work up.
- the mixture was poured into ice, and then extracted with EtOAc (3 L ⁇ 3).
- Step 4 5-Bromo-6-chloro-7-fluoronaphtho[1,2-d][1,2,3]oxadiazole.
- Step 6 8-Bromo-1-chloro-2-fluoro-6-(methoxymethoxy)naphthalene.
- a solution of 4-bromo-5-chloro-6-fluoronaphthalen-2-ol (55 g, 0.20 mol) and DIPEA (77 g, 0.10 L, 0.60 mol) in DCM (0.33 L) was cooled to 0 °C, then MOMCl (32 g, 30 mL, 0.40 mol) was added to the mixture dropwise.
- the solution was warmed to 25 °C and stirred for 12 h.
- the reaction mixture was quenched by addition saturated NaHCO 3 (aq.
- Step 7 2-(8-Chloro-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5- tetramethyl-1,3,2-dioxaborolane.
- Step 3 (R)-1-(7-Chloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3- methylpiperidin-3-ol.
- Step 5 (3R)-1-(7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8- fluoro-2-(methylsulfinyl)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol.
- the product fractions were combined, frozen, and lyophilized; the residue was redissolved in ethyl acetate, washed with aqueous potassium carbonate, and concentrated to provide 1- benzyl-3-(methyl-d3)piperidin-3-ol (1.6 g, 7.44 mmol, 56 % yield) as colorless oil.
- the racemic mixture was purified via SFC using a Chiralpak AD (21 x 250 mm 5 ⁇ m) column with a mobile phase of 10% methanol with 2% diethylamine using a flowrate of 120 mL/min, to provide two products.
- the first-eluting product (242 mg, 1.16 mmol, 8.7 % yield, ee: >99 %) was assiged the R stereochemistry.
- the reaction mixture was then diluted with saturated NH 4 Cl solution (10 mL) and extracted with EtOAc (2 ⁇ 10 mL). The organic extract was washed with saturated NaCl solution ( 20 mL) and dried over MgSO 4 . The solution was filtered and concentrated in vacuo to give the crude material, which was absorbed onto a plug of silica gel and purified by column chromatography on silica gel, eluting with a gradient of 0 - 50% EtOAc in heptane, to provide 8-bromo-1-ethyl-1,2,3,4-tetrahydronaphthalen-1-ol (0.71 g, 2.78 mmol, 87 % yield) as yellow oil.
- Step 2.8-Bromo-1-ethyl-1,2,3,4-tetrahydronaphthalene To a 25-mL round- bottomed flask was added 8-bromo-1-ethyl-1,2,3,4-tetrahydronaphthalen-1-ol (0.48 g, 1.88 mmol ) in DCM (7.5 mL). After cooling to -30 °C, triethylsilane (1.09 g, 9.41 mmol,) was added, followed by dropwise addition of TFA (0.64 g, 0.44 mL, 5.6 mmol).
- the reaction mixture was stirred for 3 h while slowly warming to rt.
- the reaction mixture was diluted with water (15 mL) and extracted with EtOAc ( 2 ⁇ 15 mL).
- the organic extract was washed with saturated NaCl solution (15 mL) and dried over MgSO 4 .
- the solution was filtered and concentrated in vacuo to give the crude material, which was absorbed onto a plug of silica gel and purified by column chromatography on silica gel, eluting with a gradient of 0 - 20% EtOAc in heptane, to provide 8-bromo-1-ethyl-1,2,3,4-tetrahydronaphthalene (0.39 g, 1.63 mmol, 87 % yield) as colorless oil.
- the reaction was purged with nitrogen for 5 min and then stirred at 65 °C for 3 h.
- the reaction mixture was concentrated and the crude material was absorbed onto a plug of silica gel and purified by column chromatography on silica gel, eluting with a gradient of 0 - 70% EtOAc in hexane, to provide 2-(4-bromo-5-ethyl-5,6,7,8- tetrahydronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.20 g, 0.55 mmol, 62 % yield) as colorless oil.
- Step 4.4-Bromo-5-ethyl-5,6,7,8-tetrahydronaphthalen-2-ol To a 50-mL round- bottomed flask was added 2-(4-bromo-5-ethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4,4,5,5- tetramethyl-1,3,2-dioxaborolane (0.20 g, 0.55 mmol) in tetrahydrofuran (1.6 mL) and water (0.6 mL).
- the reaction was then stirred at this temperature for 2 h.
- the reaction was then diluted with water (10 mL) and DCM (10 mL).
- the mixture was transferred to a separatory funnel.
- the layers were separated, and the aqueous layer was extracted with DCM (3 ⁇ 10 mL).
- the organic layers were combined, dried with sodium sulfate, filtered, and concentrated under reduced pressure to provide a crude orange oil.
- Step 2 (R)-1-(7-Chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidine-3-sulfonamide.
- Step 3 (R)-1-(7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8- fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)piperidine-3-sulfonamide.
- the vial was purged with nitrogen and the reactants were suspended in degassed tetrahydrofuran (0.9 mL) and water (90 ⁇ L). The reaction was then sealed and heated to 70 °C for 12 h. The reaction was concentrated under reduced pressure to provide a black oil.
- Step 4 (R)-1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2- (((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)piperidine-3-sulfonamide.
- Table 3 SFC conditions for chiral separation.
- Example 15 To a 20-mL vial was added 1-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen- 1-yl)-8-fluoro-2-(((2S,7aR)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)piperidin-3-ol (0.10 g, 0.16 mmol, synthesized in an analogous manner to Example 1) and sodium hydride (19 mg, 0.47 mmol, TCI America) in tetrahydrofuran (1.6 mL) at 0 °C.
- Step 1 1-(7-Chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-5,5-dimethylpiperidine-3-carboxamide.
- Step 2 1-(7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2- (((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)-5,5-dimethylpiperidine-3-carboxamide.
- the vial was purged with nitrogen and the reactants were suspended in degassed tetrahydrofuran (0.9 mL) and water (0.09 mL). The reaction was then sealed and stirred at 65 °C overnight. The reaction was then cooled to rt and concentrated under reduced pressure to afford a crude black oil.
- Step 3 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)- 2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-5,5- dimethylpiperidine-3-carboxamide.1-(7-(8-Ethyl-7-fluoro-3- (methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-5,5-dimethylpiperidine-3-carboxamide (60 mg, 0.09 mmol
- Step 2 N-((R)-1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2- (((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)piperidin-3-yl)acetamide.
- reaction mixture was purified by reverse phase HPLC to afford N-((R)-1-(7-(8- ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidin-3-yl)acetamide bis(2,2,2-trifluoroacetate) (18 mg, 0.02 mmol, 38 % yield) as yellow solid.
- Table 7 SFC Conditions for Chiral Separation.
- Table 8 Analytical Data of Examples 44 to 78.
- Step 2 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)- 2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-N- methylpiperidine-3-sulfonamide.1-(7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1- yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)-N-methylpiperidine-3-sulfonamide (47 mg, 0.066
- Example 132 To a 10-mL round-bottomed flask was added 4-(4-((R)-3-aminoazepan-1-yl)-8- fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol (30 mg, 0.05 mmol) and DIPEA (32 mg, 43 ⁇ L, 0.25 mmol, Sigma-Aldrich Corporation) in DCM (0.5 mL).
- Example 138 To an 8-mL vial was added methyl (R)-1-(7-(8-ethyl-7-fluoro-3- (methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidine-3-carboxylate (10 mg, 0.02 mmol) and 2 N sodium hydroxide (22 ⁇ L, 0.04 mmol, Sigma-Aldrich) and THF (74 ⁇ L). The reaction was stirred at rt overnight.
- Example 141 To a 10-mL round-bottomed flask was added 1-(7-(8-ethyl-7-fluoro-3- (methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)azepan-4-one (30 mg, 0.046 mmol) and sodium borohydride (5.2 mg, 0.14 mmol) in DCE (0.23 mL). A small amount of MeOH was added and the reaction was stirred at rt for 1 h.
- Example 143 To a 10-mL round-bottomed flask was added 1-(7-(8-ethyl-7-fluoro-3- (methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)azepan-4-one (20 mg, 0.03 mmol), ammonium acetate (24 mg, 0.31 mmol, Oakwood Products, Inc.) and methanol (0.6 mL).
- Example 144 To a 25-mL round-bottomed flask was added methyltriphenylphosphonium bromide in THF (41 mg, 0.12 mmol, Sigma-Aldrich Corporation) and THF (0.4 mL). LiHMDS in (1.0 M in THF, 0.1 mL, 0.11 mmol, Sigma-Aldrich Corporation) was added. The reaction was stirred for 1 h.
- Example 163 1-(7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-5- methylpiperidine-3-carboxamide (Example 163 and Example 164) Synthesized in an analogous manner to Example 162, using 5-methylpiperidine-3- carboxamide hydrochloride (CAS#: 2228678-05-3, Enamine). Isomer 1 (Example 163) was isolated as bis(2,2,2-trifluoroacetate) and as light-yellow solid.
- Step 1 4-Chloro-7-(7,8-difluoro-3-((triisopropylsilyl)oxy)naphthalen-1-yl)-8- fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidine.
- Step 2 (R)-1-(7-(7,8-Difluoro-3-((triisopropylsilyl)oxy)naphthalen-1-yl)-8- fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3- d]pyrimidin-4-yl)piperidine-3-sulfonamide.
- reaction mixture was purified by reverse phase HPLC to afford (R)-1-(7-(7,8-difluoro-3- ((triisopropylsilyl)oxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidine-3-sulfonamide (5.0 mg, 6.23 ⁇ mol, 16 % yield) as white solid.
- Step 3 (R)-1-(7-(7,8-Difluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)- 2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4- yl)piperidine-3-sulfonamide.
- Example 166 4-(4-(Azepan-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)- yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5,6-difluoronaphthalen-2-ol (Example 166) Synthesized in an analogous manner to Example 165 using azepane (CAS#: 111-49- 9, Sigma-Aldrich Corporation). The product was isolated as its TFA salt. m/z (ESI, +ve ion): 582.0 (M+H) + .
- Example 180 (R)-1-(2-((1-((Dimethylamino)methyl)cyclopropyl)methoxy)-7-(8-ethyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol (Example 180).
- Example 180 Synthesized in an analogous manner to Example 178 using (1- [(dimethylamino)methyl]cyclopropyl)methanol (CAS#: 39943-41-4, Enamine) and Lithium bis(trimethylsilyl)amide in THF solution (1 M). The product was isolated as off-white solid.
- KRAS G12D TR-FRET Assay Compounds of interest were prepared in a dose-response titration in DMSO, and 80 nL were added via Labcyte Echo to each well of a 384-well plate (Perkin Elmer 6008280).
- the His-tagged KRAS G12D protein (Amgen) was diluted to 20 nM in Assay Buffer (20 mM HEPES, pH 7.4, 10 mM MgCl 2 , 50 mM NaCl, 0.1% BSA, 0.01% Tween-20, 10 ⁇ M GDP) and 2 uL was added to the appropriate wells of the 384-well plate.
- Biotinylated KRPep-2d substrate (Amgen) was diluted to 20 nM in Assay Buffer and 2 ⁇ L was added to all wells and incubated for 1 hour at room temperature.
- Detection Reagent (0.4 nM LANCE Eu-W1024 Anti-6xHis (Perkin Elmer AD0401), 5 nM streptavidin-d2 (Cisbio 610SADLA) was prepared in Assay Buffer, then 4 ⁇ L was added to the plate and incubated for 1 hour at room temperature.
- KRAS G12D Coupled Nucleotide Exchange Assay Purified GDP-bound KRAS protein (aa 1-169), containing both G12D and C118A amino acid substitutions and an N-terminal His-tag, was pre-incubated in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl 2 , and 0.01% Triton X-100) with a compound dose- response titration for 2 hours.
- purified SOS protein (aa 564-1049) and GTP (Roche 10106399001) were added to the assay wells and incubated for an additional 30 min.
- purified GST-tagged cRAF (aa 1-149), nickel chelate AlphaLISA acceptor beads (PerkinElmer AL108R), and AlphaScreen glutathione donor beads (PerkinElmer 6765302) were added to the assay wells and incubated for 10 minutes.
- the assay plates were then read on a PerkinElmer EnVision Multilabel Reader, using AlphaScreen® technology, and data were analyzed using a 4-parameter logistic model to calculate IC 50 values.
- AsPC-1 AsPC-1 (ATCC® CRL-1682TM) cells were cultured in RPMI 1640 Medium (ThermoFisher Scientific 11875093) containing 10% fetal bovine serum (ThermoFisher Scientific 16000044) and 1x penicillin-streptomycin-glutamine (ThermoFisher Scientific 10378016). Sixteen hours prior to compound treatment, AsPC-1 cells were seeded in 96-well cell culture plates at a density of 25,000 cells/well and incubated at 37 °C, 5% CO 2 .
- a compound dose-response titration was diluted in growth media, added to appropriate wells of a cell culture plate, and then incubated at 37 °C, 5% CO 2 for 2 hours. Following compound treatment, cells were washed with ice-cold Dulbecco's phosphate-buffered saline, no Ca 2+ or Mg 2+ (ThermoFisher Scientific 14190144), and then lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 1% Igepal, 0.5% sodium deoxycholate, 150 mM NaCl, and 0.5% sodium dodecyl sulfate) containing protease inhibitors (Roche 4693132001) and phosphatase inhibitors (Roche 4906837001).
- RIPA buffer 50 mM Tris-HCl pH 7.5, 1% Igepal, 0.5% sodium deoxycholate, 150 mM NaCl, and 0.5% sodium dodecyl sulfate
- Phosphorylation of ERK1/2 in compound-treated lysates was assayed using Phospho-ERK1/2 Whole Cell Lysate kits (Meso Scale Discovery K151DWD) according to the manufacturer’s protocol. Assay plates were read on a Meso Scale Discovery Sector Imager 6000, and data were analyzed using a 4-parameter logistic model to calculate IC 50 values. Table 13: Biochemical and cellular activity of examples.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés utiles pour l'inhibition de KRAS G12D. Les composés ont une formule générale (I), les variables de la formule I étant définies dans la description. L'invention concerne également des compositions pharmaceutiques comprenant les composés, des utilisations des composés et des compositions pour traiter par exemple le cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163231543P | 2021-08-10 | 2021-08-10 | |
US202163289579P | 2021-12-14 | 2021-12-14 | |
PCT/US2022/039971 WO2023018812A1 (fr) | 2021-08-10 | 2022-08-10 | Composés hétérocycliques et procédés d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4384160A1 true EP4384160A1 (fr) | 2024-06-19 |
Family
ID=85201014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22856568.5A Pending EP4384160A1 (fr) | 2021-08-10 | 2022-08-10 | Composés hétérocycliques et procédés d'utilisation |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4384160A1 (fr) |
JP (1) | JP2024532734A (fr) |
AU (1) | AU2022325771A1 (fr) |
CA (1) | CA3228310A1 (fr) |
MX (1) | MX2024001893A (fr) |
TW (1) | TW202330529A (fr) |
WO (1) | WO2023018812A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
WO2023213269A1 (fr) * | 2022-05-06 | 2023-11-09 | Zai Lab (Shanghai) Co., Ltd. | Composés hétérocycliques à substitution amide utilisés en tant que modulateurs de kras g12d et leurs utilisations |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
WO2023244600A1 (fr) * | 2022-06-15 | 2023-12-21 | Mirati Therapeutics, Inc. | Promédicaments d'inhibiteurs pan-kras |
CN117327103A (zh) * | 2022-07-01 | 2024-01-02 | 苏州泽璟生物制药股份有限公司 | 取代嘧啶并环类抑制剂及其制备方法和应用 |
WO2024008068A1 (fr) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | Inhibiteurs de protéine mutante k-ras |
WO2024012519A1 (fr) * | 2022-07-13 | 2024-01-18 | 北京华森英诺生物科技有限公司 | Inhibiteur de pan-kras |
CN117624170A (zh) * | 2022-08-24 | 2024-03-01 | 泰励生物科技(上海)有限公司 | 具有抗kras突变肿瘤活性的化合物 |
WO2024112654A1 (fr) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Inhibiteurs de kras spirocycliques de dihydropyranopyrimidine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103588792B (zh) * | 2013-03-04 | 2016-03-23 | 中国科学院上海药物研究所 | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 |
WO2020146613A1 (fr) * | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
EP4021444A4 (fr) * | 2019-08-29 | 2023-01-04 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12d |
-
2022
- 2022-08-10 MX MX2024001893A patent/MX2024001893A/es unknown
- 2022-08-10 AU AU2022325771A patent/AU2022325771A1/en active Pending
- 2022-08-10 CA CA3228310A patent/CA3228310A1/fr active Pending
- 2022-08-10 EP EP22856568.5A patent/EP4384160A1/fr active Pending
- 2022-08-10 TW TW111130111A patent/TW202330529A/zh unknown
- 2022-08-10 JP JP2024507879A patent/JP2024532734A/ja active Pending
- 2022-08-10 WO PCT/US2022/039971 patent/WO2023018812A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2022325771A1 (en) | 2024-02-15 |
WO2023018812A1 (fr) | 2023-02-16 |
MX2024001893A (es) | 2024-02-29 |
TW202330529A (zh) | 2023-08-01 |
CA3228310A1 (fr) | 2023-02-16 |
JP2024532734A (ja) | 2024-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019216728B2 (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity | |
EP4384160A1 (fr) | Composés hétérocycliques et procédés d'utilisation | |
JP2023166614A (ja) | Shp2ホスファターゼ阻害剤およびこれらの使用方法 | |
TW202246255A (zh) | Cdk抑制劑及其使用方法 | |
EP4384177A1 (fr) | Composés hétérocycliques et procédés d'utilisation | |
EP4329757A1 (fr) | Composés hétérocycliques et procédés d'utilisation | |
TW202321242A (zh) | 雜環化合物及使用方法 | |
EP4329888A1 (fr) | Composés de 2-aminobenzothiazole et leurs procédés d'utilisation | |
AU2023221732A1 (en) | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins | |
US20230406860A1 (en) | Heterocyclic spiro compounds and methods of use | |
JP2023545545A (ja) | 複素環スピロ化合物及び使用方法 | |
WO2023159086A1 (fr) | Composés de quinazoline et leur utilisation en tant qu'inhibiteurs de protéines kras mutantes | |
CN117881397A (zh) | 杂环化合物及使用方法 | |
CN117897159A (zh) | 杂环化合物及使用方法 | |
WO2024107686A1 (fr) | Inhibiteurs de kras macrocycliques et procédés d'utilisation | |
CN117835976A (zh) | 杂环化合物及使用方法 | |
CN117561063A (zh) | 杂环化合物及使用方法 | |
TW202430532A (zh) | 大環kras抑制劑及使用方法 | |
WO2024091370A1 (fr) | Composés hétéroaromatiques bicycliques fusionnés en 5,6 | |
TW202423440A (zh) | Kras g12c突變蛋白的系鏈之雜環抑制劑及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20240227 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |